1 2 1 5 1 2 0 2 0 2 0 1 0 0 1 0 0

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2020
OF THE CONDITION AND AFFAIRS OF THE

Arcadian Health Plan, Inc.

NAIC Group Code 0119 (Current) 0119 (Prior) NAIC Company Code 12151 Employer's ID Number 20-1001348

Organized under the Laws of Washington, State of Domicile or Port of Entry WA

Country of Domicile United States of America

Licensed as business type: Health Maintenance Organization

Is HMO Federally Qualified? Yes [X] No [ ]

Incorporated/Organized 04/06/2004 Commenced Business 01/01/2005

Statutory Home Office 300 Deschutes Way SW, Suite 304 (Street and Number), Tumwater, WA, US 98501 (City or Town, State, Country and Zip Code)

Main Administrative Office 500 West Main Street (Street and Number)
Louisville, KY, US 40202 (City or Town, State, Country and Zip Code), 502-580-1000 (Area Code) (Telephone Number)

Mail Address P.O. Box 740036 (Street and Number or P.O. Box), Louisville, KY, US 40201-7436 (City or Town, State, Country and Zip Code)

Primary Location of Books and Records 500 West Main Street (Street and Number)
Louisville, KY, US 40202 (City or Town, State, Country and Zip Code), 502-580-1000 (Area Code) (Telephone Number)

Internet Website Address www.humana.com

Statutory Statement Contact Amanda Nethery (Name), 502-580-1624 (Area Code) (Telephone Number)
DOIINQUIRIES@humana.com (E-mail Address), 502-580-2099 (FAX Number)

OFFICERS

President	Bruce Dale Broussard	Chief Financial Officer	Elizabeth Lisa Ferrari #
Associate VP, Asst Gen Counsel & Corporate Secretary	Joseph Matthew Ruschell	SVP, Chief Actuary	Vanessa Marie Olson

OTHER

Alan James Bailey, VP & Treasurer	Ricky Howard Beavin, Chief Executive Officer	Andrew Joseph Besendorf III, Appointed Actuary
Courtney Danielle Durall, Assistant Corporate Secretary and Legal Advisor	Jeffrey Carl Fernandez, SVP, Medicare West and MarketPOINT	Christopher Howal Hunter, Segment President, Group & Military Business
Brian Andrew Kane, Executive VP, Finance	Steven Edward McCulley, SVP, Medicare	Matthew George Moore #, Regional President
Sean Joseph O'Reilly, SVP, Enterprise Compliance & Chief Compliance Officer	William Mark Preston, VP, Investments	Richard Donald Remmers, SVP, Employer Group Sales
George Renaudin II, SVP, Medicare East & Provider	Donald Hank Robinson, SVP, Tax	Susan Draney Schick #, SVP, Employer Group
Gilbert Alan Stewart, SVP, Medicare Divisional Leader	Daniel Andrew Tufto, SVP, Medicare Divisional Leader	

DIRECTORS OR TRUSTEES

Ricky Howard Beavin	Bruce Dale Broussard	Brian Andrew Kane

State of Kentucky
County of Jefferson SS:

The officers of this reporting entity being duly sworn, each depose and say that they are the described officers of said reporting entity, and that on the reporting period stated above, all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and that this statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities and of the condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been completed in accordance with the NAIC Annual Statement Instructions and Accounting Practices and Procedures manual except to the extent that: (1) state law may differ; or, (2) that state rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and belief, respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, that is an exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in addition to the enclosed statement.

Bruce Dale Broussard President	Joseph Matthew Ruschell Assoc. VP, Asst. General Counsel & Corporate Secretary	Alan James Bailey VP & Treasurer

Subscribed and sworn to before me this
22nd day of February, 2021

Julia Wentworth
Notary Public
January 10, 2025

Julia Wentworth
Notary Public
State at Large
Kentucky

a. Is this an original filing? ..... Yes [X] No [ ]
b. If no,
1. State the amendment number.....
2. Date filed .....
3. Number of pages attached.....

ASSETS

		Current Year			Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	991,960,054	0	991,960,054	813,908,651
2.	Stocks (Schedule D):				
	2.1 Preferred stocks	0	0	0	0
	2.2 Common stocks	0	0	0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens	0	0	0	0
	3.2 Other than first liens	0	0	0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less $ 0 encumbrances)	0	0	0	0
	4.2 Properties held for the production of income (less $ 0 encumbrances)	0	0	0	0
	4.3 Properties held for sale (less $ 0 encumbrances)	0	0	0	0
5.	Cash ($ 154,421,484 , Schedule E - Part 1), cash equivalents ($ 175,186,239 , Schedule E - Part 2) and short-term investments ($ 23,498,442 , Schedule DA)	353,106,165	0	353,106,165	272,097,911
6.	Contract loans, (including $ 0 premium notes)	0	0	0	0
7.	Derivatives (Schedule DB)	0	0	0	0
8.	Other invested assets (Schedule BA)	0	0	0	0
9.	Receivables for securities	5,000	0	5,000	0
10.	Securities lending reinvested collateral assets (Schedule DL)	0	0	0	0
11.	Aggregate write-ins for invested assets	0	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	1,345,071,219	0	1,345,071,219	1,086,006,562
13.	Title plants less $ 0 charged off (for Title insurers only)	0	0	0	0
14.	Investment income due and accrued	5,210,446	0	5,210,446	4,411,674
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	2,195,791	1,596,121	599,669	680,504
	15.2 Deferred premiums and agents' balances and installments booked but deferred and not yet due (including $ 0 earned but unbilled premiums)	0	0	0	0
	15.3 Accrued retrospective premiums ($ 19,091,737) and contracts subject to redetermination ($ 94,984,475)	114,076,212	0	114,076,212	72,949,766
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers	0	0	0	0
	16.2 Funds held by or deposited with reinsured companies	0	0	0	0
	16.3 Other amounts receivable under reinsurance contracts	0	0	0	0
17.	Amounts receivable relating to uninsured plans	33,442,902	0	33,442,902	3,693,675
18.1	Current federal and foreign income tax recoverable and interest thereon	0	0	0	0
18.2	Net deferred tax asset	11,013,173	708,621	10,304,552	7,684,598
19.	Guaranty funds receivable or on deposit	0	0	0	0
20.	Electronic data processing equipment and software	0	0	0	0
21.	Furniture and equipment, including health care delivery assets ($ 0)	0	0	0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates	0	0	0	0
23.	Receivables from parent, subsidiaries and affiliates	0	0	0	0
24.	Health care ($ 87,782,743) and other amounts receivable	97,545,304	9,762,544	87,782,760	71,425,951
25.	Aggregate write-ins for other than invested assets	22,203,537	22,203,537	0	0
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	1,630,758,583	34,270,823	1,596,487,759	1,246,852,729
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0	0
28.	Total (Lines 26 and 27)	1,630,758,583	34,270,823	1,596,487,759	1,246,852,729
	DETAILS OF WRITE-INS				
1101.		0	0	0	0
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0	0
2501.	Prepaid Commissions	10,710,045	10,710,045	0	0
2502.	Provider Contracts	6,827,832	6,827,832	0	0
2503.	Prepaid Expenses	4,665,660	4,665,660	0	0
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	22,203,537	22,203,537	0	0

LIABILITIES, CAPITAL AND SURPLUS

		Current Year			Prior Year
		1	2	3	4
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less $ 0 reinsurance ceded)	542,720,246	25,467,301	568,187,547	377,711,201
2.	Accrued medical incentive pool and bonus amounts	91,212,103	0	91,212,103	61,497,322
3.	Unpaid claims adjustment expenses	3,965,487	0	3,965,487	2,240,380
4.	Aggregate health policy reserves, including the liability of $ 0 for medical loss ratio rebate per the Public Health Service Act	12,027,117	0	12,027,117	15,257,099
5.	Aggregate life policy reserves	0	0	0	0
6.	Property/casualty unearned premium reserves	0	0	0	0
7.	Aggregate health claim reserves	0	0	0	0
8.	Premiums received in advance	3,622,565	0	3,622,565	1,465,341
9.	General expenses due or accrued	7,400,667	0	7,400,667	12,406,889
10.1	Current federal and foreign income tax payable and interest thereon (including $ 1,457,957 on realized capital gains (losses))	5,476,067	0	5,476,067	4,838,358
10.2	Net deferred tax liability	0	0	0	0
11.	Ceded reinsurance premiums payable	0	0	0	0
12.	Amounts withheld or retained for the account of others	378	0	378	1,164
13.	Remittances and items not allocated	1,085,310	0	1,085,310	1,072,548
14.	Borrowed money (including $ 0 current) and interest thereon $ 0 (including $ 0 current)	0	0	0	0
15.	Amounts due to parent, subsidiaries and affiliates	15,412,094	0	15,412,094	29,508,946
16.	Derivatives	0	0	0	0
17.	Payable for securities	2,789,563	0	2,789,563	0
18.	Payable for securities lending	0	0	0	0
19.	Funds held under reinsurance treaties (with $ 0 authorized reinsurers, $ 0 unauthorized reinsurers and $ 0 certified reinsurers)	0	0	0	0
20.	Reinsurance in unauthorized and certified ($ 0) companies	0	0	0	0
21.	Net adjustments in assets and liabilities due to foreign exchange rates	0	0	0	0
22.	Liability for amounts held under uninsured plans	5,871,837	0	5,871,837	24,009,853
23.	Aggregate write-ins for other liabilities (including $ 55,707 current)	391,795	0	391,795	75,190
24.	Total liabilities (Lines 1 to 23)	691,975,229	25,467,301	717,442,530	530,084,291
25.	Aggregate write-ins for special surplus funds	XXX	XXX	0	86,545,504
26.	Common capital stock	XXX	XXX	1,000,020	1,000,020
27.	Preferred capital stock	XXX	XXX	0	0
28.	Gross paid in and contributed surplus	XXX	XXX	624,630,733	594,630,733
29.	Surplus notes	XXX	XXX	0	0
30.	Aggregate write-ins for other than special surplus funds	XXX	XXX	0	0
31.	Unassigned funds (surplus)	XXX	XXX	253,414,476	34,592,181
32.	Less treasury stock, at cost:				
	32.1 0 shares common (value included in Line 26 $ 0)	XXX	XXX	0	0
	32.2 0 shares preferred (value included in Line 27 $ 0)	XXX	XXX	0	0
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	879,045,229	716,768,438
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	1,596,487,759	1,246,852,729
	DETAILS OF WRITE-INS				
2301.	Unclaimed Property	391,795	0	391,795	75,190
2302.					
2303.					
2398.	Summary of remaining write-ins for Line 23 from overflow page	0	0	0	0
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	391,795	0	391,795	75,190
2501.	Special Surplus - Projected HCRL Assessment for the Upcoming Year	XXX	XXX	0	86,545,504
2502.		XXX	XXX		
2503.		XXX	XXX		
2598.	Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	86,545,504
3001.		XXX	XXX	0	0
3002.		XXX	XXX		
3003.		XXX	XXX		
3098.	Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX	0	0
3099.	Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

		Current Year		Prior Year
		1 Uncovered	2 Total	3 Total
1.	Member Months	XXX	5,179,311	4,461,256
2.	Net premium income (including $ 0 non-health premium income)	XXX	5,513,801,635	4,345,827,532
3.	Change in unearned premium reserves and reserve for rate credits	XXX	0	0
4.	Fee-for-service (net of $ 0 medical expenses)	XXX	0	0
5.	Risk revenue	XXX	0	0
6.	Aggregate write-ins for other health care related revenues	XXX	0	0
7.	Aggregate write-ins for other non-health revenues	XXX	0	0
8.	Total revenues (Lines 2 to 7)	XXX	5,513,801,635	4,345,827,532
	Hospital and Medical:			
9.	Hospital/medical benefits	176,931,024	3,947,399,906	3,174,589,592
10.	Other professional services	8,164,637	182,156,901	153,707,788
11.	Outside referrals	0	0	0
12.	Emergency room and out-of-area	4,297,288	95,874,554	84,647,446
13.	Prescription drugs	12,083,717	269,593,289	200,477,858
14.	Aggregate write-ins for other hospital and medical	0	0	0
15.	Incentive pool, withhold adjustments and bonus amounts	0	82,018,318	57,651,351
16.	Subtotal (Lines 9 to 15)	201,476,666	4,577,042,968	3,671,074,034
	Less:			
17.	Net reinsurance recoveries	0	0	0
18.	Total hospital and medical (Lines 16 minus 17)	201,476,666	4,577,042,968	3,671,074,034
19.	Non-health claims (net)	0	0	0
20.	Claims adjustment expenses, including $ 143,263,369 cost containment expenses	0	169,390,602	142,602,865
21.	General administrative expenses	0	599,873,472	393,467,927
22.	Increase in reserves for life and accident and health contracts (including $ 0 increase in reserves for life only)	0	0	0
23.	Total underwriting deductions (Lines 18 through 22)	201,476,666	5,346,307,041	4,207,144,826
24.	Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	167,494,594	138,682,706
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)	0	25,164,906	30,778,918
26.	Net realized capital gains (losses) less capital gains tax of $ 2,200,822	0	7,305,925	2,408,901
27.	Net investment gains (losses) (Lines 25 plus 26)	0	32,470,832	33,187,819
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered $ 0) (amount charged off $ 0)]	0	0	0
29.	Aggregate write-ins for other income or expenses	0	49	90
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX	199,965,474	171,870,615
31.	Federal and foreign income taxes incurred	XXX	59,851,954	37,393,705
32.	Net income (loss) (Lines 30 minus 31)	XXX	140,113,520	134,476,909
	DETAILS OF WRITE-INS			
0601.		XXX	0	0
0602.		XXX		
0603		XXX		
0698.	Summary of remaining write-ins for Line 6 from overflow page	XXX	0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.		XXX	0	0
0702.		XXX		
0703		XXX		
0798.	Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.		0	0	0
1402.				
1403.				
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901.	Miscellaneous Income	0	49	90
2902.				
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page	0	0	0
2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	49	90

STATEMENT OF REVENUE AND EXPENSES (Continued)

		1 Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	716,768,438	511,484,723
34.	Net income or (loss) from Line 32	140,113,520	134,476,909
35.	Change in valuation basis of aggregate policy and claim reserves	0	0
36.	Change in net unrealized capital gains (losses) less capital gains tax of $ 0	57,176	1,977,196
37.	Change in net unrealized foreign exchange capital gain or (loss)	0	0
38.	Change in net deferred income tax	2,794,843	2,816,657
39.	Change in nonadmitted assets	(10,688,748)	(4,209,897)
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus	0	0
45.	Surplus adjustments:		
	45.1 Paid in	30,000,000	70,222,850
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital	0	0
46.	Dividends to stockholders	0	0
47.	Aggregate write-ins for gains or (losses) in surplus	0	0
48.	Net change in capital and surplus (Lines 34 to 47)	162,276,791	205,283,715
49.	Capital and surplus end of reporting period (Line 33 plus 48)	879,045,229	716,768,438
	DETAILS OF WRITE-INS		
4701.		0	0
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

CASH FLOW

		1 Current Year	2 Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance	5,471,597,596	4,351,275,375
2.	Net investment income	29,348,076	32,702,761
3.	Miscellaneous income	0	0
4.	Total (Lines 1 through 3)	5,500,945,672	4,383,978,136
5.	Benefit and loss related payments	4,376,193,281	3,544,955,586
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0
7.	Commissions, expenses paid and aggregate write-ins for deductions	820,783,200	515,839,270
8.	Dividends paid to policyholders	0	0
9.	Federal and foreign income taxes paid (recovered) net of $ 1,006,957 tax on capital gains (losses)	61,415,067	39,814,424
10.	Total (Lines 5 through 9)	5,258,391,549	4,100,609,279
11.	Net cash from operations (Line 4 minus Line 10)	242,554,123	283,368,857
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds	387,286,001	406,957,536
	12.2 Stocks	0	0
	12.3 Mortgage loans	0	0
	12.4 Real estate	0	0
	12.5 Other invested assets	0	0
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	16,143	541
	12.7 Miscellaneous proceeds	2,789,563	0
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	390,091,708	406,958,078
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds	560,771,566	711,824,925
	13.2 Stocks	0	0
	13.3 Mortgage loans	0	0
	13.4 Real estate	0	0
	13.5 Other invested assets	0	0
	13.6 Miscellaneous applications	5,000	0
	13.7 Total investments acquired (Lines 13.1 to 13.6)	560,776,566	711,824,925
14.	Net increase (decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(170,684,858)	(304,866,847)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock	30,000,000	70,000,000
	16.3 Borrowed funds	0	0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
	16.5 Dividends to stockholders	0	0
	16.6 Other cash provided (applied)	(20,861,010)	55,359,246
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	9,138,990	125,359,246
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	81,008,255	103,861,256
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year	272,097,911	168,236,655
	19.2 End of year (Line 18 plus Line 19.1)	353,106,165	272,097,911

Note: Supplemental disclosures of cash flow information for non-cash transactions:

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

		1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other Health	10 Other Non-Health
1.	Net premium income	5,513,801,635	0	0	0	0	0	5,513,801,635	0	0	0
2.	Change in unearned premium reserves and reserve for rate credit	0	0	0	0	0	0	0	0	0	0
3.	Fee-for-service (net of $ 0 medical expenses)	0	0	0	0	0	0	0	0	0	XXX
4.	Risk revenue	0	0	0	0	0	0	0	0	0	XXX
5.	Aggregate write-ins for other health care related revenues	0	0	0	0	0	0	0	0	0	XXX
6.	Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
7.	Total revenues (Lines 1 to 6)	5,513,801,635	0	0	0	0	0	5,513,801,635	0	0	0
8.	Hospital/medical benefits	3,947,399,906	0	0	0	0	0	3,947,399,906	0	0	XXX
9.	Other professional services	182,156,901	0	0	0	0	0	182,156,901	0	0	XXX
10.	Outside referrals	0	0	0	0	0	0	0	0	0	XXX
11.	Emergency room and out-of-area	95,874,554	0	0	0	0	0	95,874,554	0	0	XXX
12.	Prescription drugs	269,593,289	0	0	0	0	0	269,593,289	0	0	XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	82,018,318	0	0	0	0	0	82,018,318	0	0	XXX
15.	Subtotal (Lines 8 to 14)	4,577,042,968	0	0	0	0	0	4,577,042,968	0	0	XXX
16.	Net reinsurance recoveries	0	0	0	0	0	0	0	0	0	XXX
17.	Total medical and hospital (Lines 15 minus 16)	4,577,042,968	0	0	0	0	0	4,577,042,968	0	0	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
19.	Claims adjustment expenses including $ 143,263,369 cost containment expenses	169,390,602	0	0	0	0	0	169,390,602	0	0	0
20.	General administrative expenses	599,873,472	0	0	0	0	0	599,873,472	0	0	0
21.	Increase in reserves for accident and health contracts	0	0	0	0	0	0	0	0	0	XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
23.	Total underwriting deductions (Lines 17 to 22)	5,346,307,041	0	0	0	0	0	5,346,307,041	0	0	0
24.	Total underwriting gain or (loss) (Line 7 minus Line 23)	167,494,594	0	0	0	0	0	167,494,594	0	0	0
	DETAILS OF WRITE-INS										
0501.											XXX
0502.											XXX
0503.											XXX
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	XXX
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	XXX
0601.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.											XXX
1302.											XXX
1303.											XXX
1398.	Summary of remaining write-ins for Line 13 from overflow page	0	0	0	0	0	0	0	0	0	XXX
1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	0	0	0	0	0	0	XXX

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

Line of Business	1 Direct Business	2 Reinsurance Assumed	3 Reinsurance Ceded	4 Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical)	0	0	0	0
2. Medicare Supplement	0	0	0	0
3. Dental only	0	0	0	0
4. Vision only	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0
6. Title XVIII - Medicare	5,513,801,635	0	0	5,513,801,635
7. Title XIX - Medicaid	0	0	0	0
8. Other health	0	0	0	0
9. Health subtotal (Lines 1 through 8)	5,513,801,635	0	0	5,513,801,635
10. Life	0	0	0	0
11. Property/casualty	0	0	0	0
12. Totals (Lines 9 to 11)	5,513,801,635	0	0	5,513,801,635

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

	1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other Health	10 Other Non-Health
1. Payments during the year:										
1.1 Direct	4,324,132,241	0	0	0	0	0	4,324,132,241	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
1.4 Net	4,324,132,241	0	0	0	0	0	4,324,132,241	0	0	0
2. Paid medical incentive pools and bonuses	52,303,537	0	0	0	0	0	52,303,537	0	0	0
3. Claim liability December 31, current year from Part 2A:										
3.1 Direct	568,187,547	0	0	0	0	0	568,187,547	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net	568,187,547	0	0	0	0	0	568,187,547	0	0	0
4. Claim reserve December 31, current year from Part 2D:										
4.1 Direct	0	0	0	0	0	0	0	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	0	0	0	0	0	0	0	0	0	0
5. Accrued medical incentive pools and bonuses, current year	91,212,103	0	0	0	0	0	91,212,103	0	0	0
6. Net healthcare receivables (a)	19,583,938	0	0	0	0	0	19,583,938	0	0	0
7. Amounts recoverable from reinsurers December 31, current year	0	0	0	0	0	0	0	0	0	0
8. Claim liability December 31, prior year from Part 2A:										
8.1 Direct	377,711,201	0	0	0	0	0	377,711,201	0	0	0
8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
8.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
8.4 Net	377,711,201	0	0	0	0	0	377,711,201	0	0	0
9. Claim reserve December 31, prior year from Part 2D:										
9.1 Direct	0	0	0	0	0	0	0	0	0	0
9.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
9.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
9.4 Net	0	0	0	0	0	0	0	0	0	0
10. Accrued medical incentive pools and bonuses, prior year	61,497,322	0	0	0	0	0	61,497,322	0	0	0
11. Amounts recoverable from reinsurers December 31, prior year	0	0	0	0	0	0	0	0	0	0
12. Incurred Benefits:										
12.1 Direct	4,495,024,650	0	0	0	0	0	4,495,024,650	0	0	0
12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
12.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
12.4 Net	4,495,024,650	0	0	0	0	0	4,495,024,650	0	0	0
13. Incurred medical incentive pools and bonuses	82,018,318	0	0	0	0	0	82,018,318	0	0	0

(a) Excludes $ 0 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other Health	10 Other Non-Health
1. Reported in Process of Adjustment:										
1.1 Direct	177,299,807	0	0	0	0	0	177,299,807	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
1.4 Net	177,299,807	0	0	0	0	0	177,299,807	0	0	0
2. Incurred but Unreported:										
2.1 Direct	254,060,502	0	0	0	0	0	254,060,502	0	0	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
2.4 Net	254,060,502	0	0	0	0	0	254,060,502	0	0	0
3. Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	136,827,239	0	0	0	0	0	136,827,239	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net	136,827,239	0	0	0	0	0	136,827,239	0	0	0
4. TOTALS:										
4.1 Direct	568,187,547	0	0	0	0	0	568,187,547	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	568,187,547	0	0	0	0	0	568,187,547	0	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

Line of Business	Claims Paid During the Year		Claim Reserve and Claim Liability December 31 of Current Year		5	6
	1 On Claims Incurred Prior to January 1 of Current Year	2 On Claims Incurred During the Year	3 On Claims Unpaid December 31 of Prior Year	4 On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Estimated Claim Reserve and Claim Liability December 31 of Prior Year
1. Comprehensive (hospital and medical)	0	0	0	0	0	0
2. Medicare Supplement	0	0	0	0	0	0
3. Dental Only	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0	0	0
6. Title XVIII - Medicare	303,778,635	4,020,353,607	5,945,195	562,242,352	309,723,830	377,711,201
7 Title XIX - Medicaid	0	0	0	0	0	0
8. Other health	0	0	0	0	0	0
9. Health subtotal (Lines 1 to 8)	303,778,635	4,020,353,607	5,945,195	562,242,352	309,723,830	377,711,201
10. Healthcare receivables (a)	916,756	96,628,530	0	0	916,756	77,961,349
11. Other non-health	0	0	0	0	0	0
12. Medical incentive pools and bonus amounts	52,303,537	0	2,464,381	88,747,722	54,767,918	61,497,322
13. Totals (Lines 9 - 10 + 11 + 12)	355,165,415	3,923,725,077	8,409,576	650,990,074	363,574,992	361,247,174

(a) Excludes $ 0 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

Section A - Paid Health Claims - Title XVIII

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2016	2 2017	3 2018	4 2019	5 2020
1.	Prior	6,576	6,758	6,724	6,709	6,707
2.	2016	709,095	765,510	764,123	764,243	764,151
3.	2017	XXX	676,280	718,786	717,190	717,314
4.	2018	XXX	XXX	2,635,321	2,848,985	2,846,913
5.	2019	XXX	XXX	XXX	3,332,824	3,690,948
6.	2020	XXX	XXX	XXX	XXX	4,020,354

Section B - Incurred Health Claims - Title XVIII

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2016	2 2017	3 2018	4 2019	5 2020
1.	Prior	6,630	6,775	6,724	6,709	6,707
2.	2016	786,127	766,812	764,314	764,243	764,151
3.	2017	XXX	724,151	719,126	717,350	717,314
4.	2018	XXX	XXX	2,928,748	2,859,564	2,847,234
5.	2019	XXX	XXX	XXX	3,761,293	3,699,037
6.	2020	XXX	XXX	XXX	XXX	4,671,344

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

Years in which Premiums were Earned and Claims were Incurred		1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1.	2016	812,894	764,151	7,267	1.0	771,418	94.9	0	0	771,418	94.9
2.	2017	803,575	717,314	6,822	1.0	724,136	90.1	0	0	724,136	90.1
3.	2018	3,417,678	2,846,913	27,074	1.0	2,873,987	84.1	321	2	2,874,310	84.1
4.	2019	4,345,828	3,690,948	35,101	1.0	3,726,049	85.7	8,089	49	3,734,187	85.9
5.	2020	5,513,802	4,020,354	38,234	1.0	4,058,588	73.6	650,990	3,915	4,713,493	85.5

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

Section A - Paid Health Claims - Grand Total

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2016	2 2017	3 2018	4 2019	5 2020
1. Prior	6,576	6,758	6,724	6,709	6,707
2. 2016	709,095	765,510	764,123	764,243	764,151
3. 2017	XXX	676,280	718,786	717,190	717,314
4. 2018	XXX	XXX	2,635,321	2,848,985	2,846,913
5. 2019	XXX	XXX	XXX	3,332,824	3,690,948
6. 2020	XXX	XXX	XXX	XXX	4,020,354

Section B - Incurred Health Claims - Grand Total

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2016	2 2017	3 2018	4 2019	5 2020
1. Prior	6,630	6,775	6,724	6,709	6,707
2. 2016	786,127	766,812	764,314	764,243	764,151
3. 2017	XXX	724,151	719,126	717,350	717,314
4. 2018	XXX	XXX	2,928,748	2,859,564	2,847,234
5. 2019	XXX	XXX	XXX	3,761,293	3,699,037
6. 2020	XXX	XXX	XXX	XXX	4,671,344

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2016	812,894	764,151	7,267	1.0	771,418	94.9	0	0	771,418	94.9
2. 2017	803,575	717,314	6,822	1.0	724,136	90.1	0	0	724,136	90.1
3. 2018	3,417,678	2,846,913	27,074	1.0	2,873,987	84.1	321	2	2,874,310	84.1
4. 2019	4,345,828	3,690,948	35,101	1.0	3,726,049	85.7	8,089	49	3,734,187	85.9
5. 2020	5,513,802	4,020,354	38,234	1.0	4,058,588	73.6	650,990	3,915	4,713,493	85.5

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

		1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other
1.	Unearned premium reserves	0	0	0	0	0	0	0	0	0
2.	Additional policy reserves (a)	0	0	0	0	0	0	0	0	0
3.	Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0
4.	Reserve for rate credits or experience rating refunds (including $ 0) for investment income	1,937,486	0	0	0	0	0	1,937,486	0	0
5.	Aggregate write-ins for other policy reserves	10,089,631	0	0	0	0	0	10,089,631	0	0
6.	Totals (gross)	12,027,117	0	0	0	0	0	12,027,117	0	0
7.	Reinsurance ceded	0	0	0	0	0	0	0	0	0
8.	Totals (Net)(Page 3, Line 4)	12,027,117	0	0	0	0	0	12,027,117	0	0
9.	Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	0
10.	Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0
11.	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0
12.	Totals (gross)	0	0	0	0	0	0	0	0	0
13.	Reinsurance ceded	0	0	0	0	0	0	0	0	0
14.	Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0
	DETAILS OF WRITE-INS									
0501.	Risk Adjustment Premium Payable	10,089,631	0	0	0	0	0	10,089,631	0	0
0502.										
0503.										
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	10,089,631	0	0	0	0	0	10,089,631	0	0
1101.										
1102.										
1103.										
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0

(a) Includes $ 0 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

		Claim Adjustment Expenses		3	4	5
		1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent ($ 0 for occupancy of own building)	1,071,174	234,048	3,646,272	7,295	4,958,789
2.	Salary, wages and other benefits	58,183,505	11,105,215	167,169,036	331,813	236,789,569
3.	Commissions (less $ 0 ceded plus $ 0 assumed)	0	0	122,395,154	6,615	122,401,769
4.	Legal fees and expenses	950,741	169,697	1,477,568	2,696	2,600,702
5.	Certifications and accreditation fees	13,534	8,745	136,237	272	158,788
6.	Auditing, actuarial and other consulting services	2,965,758	619,254	8,761,170	17,341	12,363,523
7.	Traveling expenses	337,979	70,851	1,015,187	2,012	1,426,029
8.	Marketing and advertising	8,718,242	1,899,799	29,449,836	58,891	40,126,768
9.	Postage, express and telephone	5,190,017	1,110,482	16,737,565	32,928	23,070,991
10.	Printing and office supplies	2,170,798	461,494	6,857,354	13,650	9,503,297
11.	Occupancy, depreciation and amortization	725,615	158,553	2,475,227	(17)	3,359,378
12.	Equipment	608,450	132,952	2,071,414	4,143	2,816,959
13.	Cost or depreciation of EDP equipment and software	2,643,202	577,090	9,011,886	(16,599)	12,215,579
14.	Outsourced services including EDP, claims, and other services	52,252,988	8,267,029	100,850,749	195,610	161,566,376
15.	Boards, bureaus and association fees	665,687	113,730	798,749	1,392	1,579,558
16.	Insurance, except on real estate	324,811	70,386	1,079,509	2,156	1,476,861
17.	Collection and bank service charges	709,811	155,097	2,416,409	4,834	3,286,152
18.	Group service and administration fees	4,194,614	637,091	1,252,441	668	6,084,814
19.	Reimbursements by uninsured plans	0	0	0	0	0
20.	Reimbursements from fiscal intermediaries	0	0	0	0	0
21.	Real estate expenses	1,170,421	255,743	3,984,467	7,971	5,418,602
22.	Real estate taxes	0	0	0	0	0
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes	0	0	11,018,820	6	11,018,826
	23.2 State premium taxes	0	0	0	0	0
	23.3 Regulatory authority licenses and fees	0	0	2,109,610	2,956	2,112,567
	23.4 Payroll taxes	0	0	10,027,717	19,912	10,047,629
	23.5 Other (excluding federal income and real estate taxes)	0	0	92,015,990	637	92,016,627
24.	Investment expenses not included elsewhere	128,065	27,983	437,627	(786)	592,889
25.	Aggregate write-ins for expenses	237,957	51,995	2,677,475	450	2,967,877
26.	Total expenses incurred (Lines 1 to 25)	143,263,369	26,127,233	599,873,472	696,846	(a) 769,960,919
27.	Less expenses unpaid December 31, current year	0	3,965,487	7,400,667	0	11,366,154
28.	Add expenses unpaid December 31, prior year	0	2,240,380	12,406,889	0	14,647,269
29.	Amounts receivable relating to uninsured plans, prior year	0	0	3,693,675	0	3,693,675
30.	Amounts receivable relating to uninsured plans, current year	0	0	33,442,902	0	33,442,902
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	143,263,369	24,402,127	634,628,921	696,846	802,991,262
	DETAILS OF WRITE-INS					
2501.	Miscellaneous Administrative Expenses	237,957	51,995	2,677,475	450	2,967,877
2502.						
2503.						
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	237,957	51,995	2,677,475	450	2,967,877

(a) Includes management fees of $ 483,600,121 to affiliates and $ 0 to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

		1 Collected During Year	2 Earned During Year
1.	U.S. government bonds	(a) 447,850	428,035
1.1	Bonds exempt from U.S. tax	(a) 0	0
1.2	Other bonds (unaffiliated)	(a) 21,061,918	21,941,718
1.3	Bonds of affiliates	(a) 0	0
2.1	Preferred stocks (unaffiliated)	(b) 0	0
2.11	Preferred stocks of affiliates	(b) 0	0
2.2	Common stocks (unaffiliated)	0	0
2.21	Common stocks of affiliates	0	0
3.	Mortgage loans	(c) 0	0
4.	Real estate	(d) 0	0
5	Contract Loans	0	0
6	Cash, cash equivalents and short-term investments	(e) 3,544,490	3,483,278
7	Derivative instruments	(f) 0	0
8.	Other invested assets	0	0
9.	Aggregate write-ins for investment income	8,722	8,722
10.	Total gross investment income	25,062,980	25,861,752
11.	Investment expenses		(g) 673,334
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g) 23,512
13.	Interest expense		(h) 0
14.	Depreciation on real estate and other invested assets		(i) 0
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		696,846
17.	Net investment income (Line 10 minus Line 16)		25,164,906
	DETAILS OF WRITE-INS		
0901.	Miscellaneous Investment Income	8,722	8,722
0902.			
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	8,722	8,722
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0

(a) Includes $ (278,416) accrual of discount less $ 4,703,526 amortization of premium and less $ 1,326,898 paid for accrued interest on purchases.

(b) Includes $ 0 accrual of discount less $ 0 amortization of premium and less $ 0 paid for accrued dividends on purchases.

(c) Includes $ 0 accrual of discount less $ 0 amortization of premium and less $ 0 paid for accrued interest on purchases.

(d) Includes $ 0 for company's occupancy of its own buildings; and excludes $ 0 interest on encumbrances.

(e) Includes $ 3,069,545 accrual of discount less $ 174,775 amortization of premium and less $ 258,524 paid for accrued interest on purchases.

(f) Includes $ 0 accrual of discount less $ 0 amortization of premium.

(g) Includes $. 0 investment expenses and $ 0 investment taxes, licenses and fees, excluding federal income taxes, attributable to segregated and Separate Accounts.

(h) Includes $ 0 interest on surplus notes and $ 0 interest on capital notes.

(i) Includes $ 0 depreciation on real estate and $ 0 depreciation on other invested assets.

EXHIBIT OF CAPITAL GAINS (LOSSES)

		1 Realized Gain (Loss) On Sales or Maturity	2 Other Realized Adjustments	3 Total Realized Capital Gain (Loss) (Columns 1 + 2)	4 Change in Unrealized Capital Gain (Loss)	5 Change in Unrealized Foreign Exchange Capital Gain (Loss)
1.	U.S. Government bonds	6,551	0	6,551	0	0
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)	9,484,053	0	9,484,053	57,176	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0	0	0
5.	Contract loans	0	0	0	0	0
6.	Cash, cash equivalents and short-term investments	16,143	0	16,143	0	0
7.	Derivative instruments	0	0	0	0	0
8.	Other invested assets	0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	9,506,747	0	9,506,747	57,176	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

		1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)	0	0	0
2.	Stocks (Schedule D):			
	2.1 Preferred stocks	0	0	0
	2.2 Common stocks	0	0	0
3.	Mortgage loans on real estate (Schedule B):			
	3.1 First liens	0	0	0
	3.2 Other than first liens	0	0	0
4.	Real estate (Schedule A):			
	4.1 Properties occupied by the company	0	0	0
	4.2 Properties held for the production of income	0	0	0
	4.3 Properties held for sale	0	0	0
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)	0	0	0
6.	Contract loans	0	0	0
7.	Derivatives (Schedule DB)	0	0	0
8.	Other invested assets (Schedule BA)	0	0	0
9.	Receivables for securities	0	0	0
10.	Securities lending reinvested collateral assets (Schedule DL)	0	0	0
11.	Aggregate write-ins for invested assets	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	0	0	0
13.	Title plants (for Title insurers only)	0	0	0
14.	Investment income due and accrued	0	0	0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection	1,596,121	1,510,451	(85,670)
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due	0	0	0
	15.3 Accrued retrospective premiums and contracts subject to redetermination	0	0	0
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers	0	0	0
	16.2 Funds held by or deposited with reinsured companies	0	0	0
	16.3 Other amounts receivable under reinsurance contracts	0	0	0
17.	Amounts receivable relating to uninsured plans	0	0	0
18.1	Current federal and foreign income tax recoverable and interest thereon	0	0	0
18.2	Net deferred tax asset	708,621	533,732	(174,889)
19.	Guaranty funds receivable or on deposit	0	0	0
20.	Electronic data processing equipment and software	0	0	0
21.	Furniture and equipment, including health care delivery assets	0	0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates	0	0	0
23.	Receivable from parent, subsidiaries and affiliates	0	0	0
24.	Health care and other amounts receivable	9,762,544	6,535,425	(3,227,119)
25.	Aggregate write-ins for other than invested assets	22,203,537	15,002,467	(7,201,070)
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	34,270,823	23,582,076	(10,688,748)
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0
28.	Total (Lines 26 and 27)	34,270,823	23,582,076	(10,688,748)
	DETAILS OF WRITE-INS			
1101.		0	0	0
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid Commissions	10,710,045	8,956,901	(1,753,144)
2502.	Provider Contracts	6,827,832	5,973,950	(853,881)
2503.	Prepaid Expenses	4,665,660	0	(4,665,660)
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	71,616	71,616
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	22,203,537	15,002,467	(7,201,070)

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

	Source of Enrollment	Total Members at End of 1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	6 Current Year Member Months
1.	Health Maintenance Organizations	375,010	405,610	413,468	423,273	427,113	4,980,739
2.	Provider Service Organizations	0	0	0	0	0	0
3.	Preferred Provider Organizations	10,098	15,666	15,446	17,247	18,397	198,572
4.	Point of Service	0	0	0	0	0	0
5.	Indemnity Only	0	0	0	0	0	0
6.	Aggregate write-ins for other lines of business	0	0	0	0	0	0
7.	Total	385,108	421,276	428,914	440,520	445,510	5,179,311
	DETAILS OF WRITE-INS						
0601.							
0602.							
0603.							
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

NOTES TO THE FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The financial statements of the Company are presented on the basis of accounting practices prescribed or permitted by the Washington Office of Insurance.

The Washington Office of Insurance (the Office) recognizes only statutory accounting practices prescribed or permitted by the State of Washington for determining and reporting the financial condition and results of operations of an insurance company, for determining its solvency under the Washington Insurance Law. The National Association of Insurance Commissioners' (NAIC) Accounting Practices and Procedures manual (NAIC SSAP) has been adopted as a component of prescribed or permitted practices by the State of Washington. The Commissioner of Insurance has the right to permit other specific practices that deviate from prescribed practices. No deviations from the Codification currently exist.

A reconciliation of the Company's net income and capital and surplus between NAIC SSAP and practices prescribed and permitted by the State of Washington is shown below:

	SSAP #	F/S Page	F/S Line #	2020	2019
Net Income					
1. Arcadian Health Plan, Inc. Washington basis	xxx	xxx	xxx	$ 140,113,520	$ 134,476,909
2. State Prescribed Practices that is an increase/(decrease) NAIC SSAP				-	-
3. State Permitted Practices that is an increase/(decrease) NAIC SSAP				-	-
4. NAIC SSAP	xxx	xxx	xxx	$ 140,113,520	$ 134,476,909
Surplus					
5. Arcadian Health Plan, Inc. Washington basis	xxx	xxx	xxx	$ 879,045,229	$ 716,768,438
6. State Prescribed Practices that is an increase/(decrease) NAIC SSAP				-	-
7. State Permitted Practices that is an increase/(decrease) NAIC SSAP				-	-
8. NAIC SSAP	xxx	xxx	xxx	$ 879,045,229	$ 716,768,438

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results could differ from those estimates.

C. Accounting Policy

Premiums are reported as earned in the period in which members are entitled to receive services, and are net of retroactive membership adjustments. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. Premiums received prior to such period are recorded as advance premiums.

Benefits incurred and loss adjustment expenses include claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses, legal and administrative costs to settle claims, and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care provided prior to the date of the statements of admitted assets, liabilities and surplus. Capitation payments represent monthly contractual fees disbursed to participating primary care physicians, and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members' prescription drug benefits, net of rebates from drug manufacturers.

In addition, the Company uses the following accounting policies:

(1) Short-term investments include investments mainly in U.S. Government obligations with a maturity of twelve months or less from the date of purchase. Short-term investments are recorded at amortized cost. The carrying value of short-term investments approximates fair value due to the short-term maturities of the investments.

(2-4) Investments are valued and classified in accordance with methods prescribed by the NAIC. Bonds with an NAIC rating of 1 or 2 are carried at amortized cost, with all other bonds being recorded at the lower of amortized cost or fair value; redeemable preferred stocks are carried at amortized cost; and non-redeemable preferred stocks are carried at fair value. Common stocks are carried at fair value.

The Company regularly evaluates investment securities for impairment. For all securities other than loan-backed and structured securities, the Company considers factors affecting the investee, factors affecting the industry the investee operates within, and general debt and equity market trends. The Company also considers the length of time an investment's fair value has been below carrying value, the near term prospects for recovery to carrying value, and the Company's intent and ability to hold the investment until maturity or market recovery is realized. If and when a determination is made that a decline in fair value below the cost basis is other-than-temporary, the related investment is written down to its estimated fair value through earnings.

Amortization of bond premium or discount is computed using the scientific interest method.

NOTES TO THE FINANCIAL STATEMENTS

Income from investments is recorded on an accrual basis. For the purpose of determining realized gains and losses, the cost of securities sold is based upon specific identification. Investment income due and accrued over 90 days past due is nonadmitted.

(5) Not Applicable.

(6) For loan backed and structured securities where the securities fair value is less than the amortized cost, the Company considers several factors to determine if the security's impairment is other-than-temporary. If the Company has the intent to sell the security or if the Company does not have the intent and ability to retain the security until recovery of its fair value, the related investment is written down to its estimated fair value through earnings. If, however, the Company has the intent and ability to retain the security until recovery of its fair value, the Company considers factors affecting the investee, factors affecting the industry the investee operates within, and general debt and equity market trends. The Company also considers the length of time an investment's fair value has been below carrying value and the near term prospects for recovery to carrying value. If the determination is made, based on these factors, that the Company does expect to recover the entire amortized cost of the security, then an other-than-temporary impairment has not occurred. If, however, the determination is made that the Company does not expect to recover the entire amortized cost of the security based on the factors noted above, the Company recognizes a realized loss in earnings for the non-interest related decline. No loss is recognized for the interest impairment.

(7) Not Applicable.

(8) Not Applicable.

(9) Not Applicable.

(10-11) The estimates of future medical benefit payments are developed using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical development such as claim inventory levels and claim receipt patterns, and other relevant factors. Corresponding administrative costs to process outstanding claims are estimated and accrued. Estimates of future payments relating to services incurred in the current and prior periods are continually reviewed by management and adjusted as necessary.

The Company assesses the profitability of its contracts for providing health insurance coverage to its members when current operating results or forecasts indicate probable future losses. The Company records a premium deficiency liability in current operations to the extent that the sum of expected future medical costs, claim adjustment expenses and maintenance costs exceed related future premiums. Investment income is not contemplated in the calculation of the premium deficiency liability.

Management believes the Company's benefits payable and loss adjustment expense are adequate to cover future claims and loss adjustment expense payments required, however, such estimates are based on knowledge of current events and anticipated future events and, therefore, the actual liability could differ from the amounts provided.

(12) The Company has not modified its capitalization policy from the prior period.

Equipment is stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives generally ranging from three to five years. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.

The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements. The temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled.

(13) The Company estimates anticipated Pharmacy Rebate Receivables using the analysis of historical recovery patterns.

(14) Not Applicable.

(15) Not Applicable.

D. Going Concern

Management of the Company has evaluated the Company's ability to continue as a going concern under SSAP No. 1, *Accounting Policies, Risks & Uncertainties, and Other Disclosures* (SSAP No. 1). Based on this evaluation, Management has determined that there is no substantial doubt about the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

Not Applicable.

3. Business Combinations and Goodwill

A. Statutory Purchase Method

Not Applicable.

B. Statutory Merger

Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

C. Assumption Reinsurance

Not Applicable.

D. Impairment Loss

Not Applicable.

4. Discontinued Operations

Not Applicable.

5. Investments

A. Mortgage Loans, Including Mezzanine Real Estate Loans

Not Applicable.

B. Debt Restructuring

Not Applicable.

C. Reverse Mortgages

Not Applicable.

D. Loan-Backed Securities

(1) Prepayment assumptions for mortgage-backed/loan-backed and structured securities were obtained from industry market sources.

(2) Not Applicable.

(3) Not Applicable.

(4) The Company does not have any investments in an other-than-temporary impairment position at December 31, 2020.

Gross unrealized losses and related fair value of temporarily impaired securities that have been in a continuous unrealized loss position were as follows at December 31, 2020:

(a) The aggregate amount of unrealized losses:

1.	Less than Twelve Months	$	(195,202)
2.	Twelve Months or Longer	$	(33,244)

(b) The aggregate related fair value of securities with unrealized losses:

1.	Less than Twelve Months	$	57,666,199
2.	Twelve Months or Longer	$	15,161,756

(5) Unrealized losses are primarily due to increases in market interest rates and tighter liquidity conditions in the current markets than when the securities were purchased. All issuers of securities trading at an unrealized loss remain current on all contractual payments and the Company believes it is probable that all amounts due according to the contractual terms of the debt securities are collectible. After taking into account these and other factors, including the severity of the decline and the Company's ability and intent to hold these securities until recovery or maturity, the Company determined the unrealized losses on these investment securities were temporary and, as such, no impairment was required.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

(1) The Company has no repurchase agreements or securities lending transactions.

(2) The Company has not pledged any of its assets as collateral.

(3-7) Not Applicable.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not Applicable.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not Applicable.

H. Repurchase Agreements Transactions Accounted for as a Sale

Not Applicable.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

NOTES TO THE FINANCIAL STATEMENTS

Not Applicable.

J. Real Estate

Not Applicable.

K. Low-Income Housing Tax Credits (LIHTC)

Not Applicable.

L. Restricted Assets

(1) Restricted Assets (Including Pledged)

Restricted Asset Category	1 Total Gross (Admitted & Nonadmitted) Restricted from Current Year	2 Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	3 Increase/ (Decrease) (1 minus 2)	4 Total Current Year Nonadmitted Restricted	5 Total Current Year Admitted Restricted (1 minus 4)	6 Percentage Gross (Admitted & Nonadmitted) Restricted to Total Assets (a)	7 Percentage Admitted Restricted to Total Admitted Assets (b)
a. Subject to contractual obligation for which liability is not shown	$ -	$ -	$ -	$ -	$ -	-%	-%
b. Collateral held under security lending agreements	-	-	-	-	-	-	-
c. Subject to repurchase agreements	-	-	-	-	-	-	-
d. Subject to reverse repurchase agreements	-	-	-	-	-	-	-
e. Subject to dollar repurchase agreements	-	-	-	-	-	-	-
f. Subject to dollar reverse repurchase agreements	-	-	-	-	-	-	-
g. Placed under option contracts	-	-	-	-	-	-	-
h. Letter stock or securities restricted to sale – excluding FHLB capital stock	-	-	-	-	-	-	-
i. FHLB capital stock	-	-	-	-	-	-	-
j. On deposit with states	11,601,925	12,318,518	(716,593)	-	11,601,925	0.71%	0.73%
k. On deposit with other regulatory bodies	-	-	-	-	-	-	-
l. Pledged collateral to FHLB (including assets backing funding agreements)	-	-	-	-	-	-	-
m. Pledged as collateral not captured in other categories	-	-	-	-	-	-	-
n. Other restricted assets	-	-	-	-	-	-	-
o. Total Restricted Assets	$ 11,601,925	$ 12,318,518	$ (716,593)	-	$ 11,601,925	0.71%	0.73%

(2) Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not Applicable.

(3) Detail of Other Restricted Assets Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not Applicable.

(4) Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

Not Applicable.

M. Working Capital Finance Investments

Not Applicable.

N. Offsetting and Netting of Assets and Liabilities

Not Applicable.

O. 5GI* Securities

Not Applicable.

P. Short Sales

Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

Q. Prepayment Penalty and Acceleration Fees

(1)	Number of CUSIPS		1
(2)	Aggregate Amount of Investment Income	$	4,986

6. Joint Ventures, Partnerships and Limited Liability Companies

A. The Company has no investments in Joint Ventures, Partnerships or Limited Liability Companies that exceed 10.0 percent of its admitted assets.

B. The Company did not recognize any impairment write down for its investments in Joint Ventures, Partnerships and Limited Liability Companies during the statement periods.

7. Investment Income

A. Due and accrued income was excluded from surplus on the following basis:

All investment income due and accrued with amounts that are over 90 days past due with the exception of mortgage loans in default.

B. The total amount excluded was $0.

8. Derivative Instruments

Not Applicable.

9. Income Taxes

A. Deferred Tax Assets/(Liabilities)

(1) The components of the net admitted deferred tax asset/(liability) by tax character were as follows:

		December 31, 2020		
		Ordinary	Capital	Total
a.	Gross deferred tax assets	$ 11,058,818	$ 1,350	$ 11,060,168
b.	Statutory valuation allowance adjustments	-	(1,350)	(1,350)
c.	Adjusted gross deferred tax assets	11,058,818	-	11,058,818
d.	Deferred tax assets nonadmitted	(708,621)	-	(708,621)
e.	Net admitted deferred tax assets	10,350,197	-	10,350,197
f.	Deferred tax liabilities	(45,645)	-	(45,645)
g.	Net admitted deferred tax asset/(liability)	$ 10,304,552	$ -	$ 10,304,552

		December 31, 2019		
		Ordinary	Capital	Total
a.	Gross deferred tax assets	$ 8,271,943	$ 13,378	$ 8,285,321
b.	Statutory valuation allowance adjustments	-	(13,378)	(13,378)
c.	Adjusted gross deferred tax assets	8,271,943	-	8,271,943
d.	Deferred tax assets nonadmitted	(533,732)	-	(533,732)
e.	Net admitted deferred tax assets	7,738,211	-	7,738,211
f.	Deferred tax liabilities	(53,613)	-	(53,613)
g.	Net admitted deferred tax asset/(liability)	$ 7,684,598	$ -	$ 7,684,598

		Change		
		Ordinary	Capital	Total
a.	Gross deferred tax assets	$ 2,786,875	$ (12,028)	$ 2,774,847
b.	Statutory valuation allowance adjustments	-	12,028	12,028
c.	Adjusted gross deferred tax assets	2,786,875	-	2,786,875
d.	Deferred tax assets nonadmitted	(174,889)	-	(174,889)
e.	Net admitted deferred tax assets	2,611,986	-	2,611,986
f.	Deferred tax liabilities	7,968	-	7,968
g.	Net admitted deferred tax asset/(liability)	$ 2,619,954	$ -	$ 2,619,954

(2) The amount of admitted adjusted gross deferred tax assets under SSAP No. 101 were as follows:

		December 31, 2020		
		Ordinary	Capital	Total
a.	Federal income taxes paid in prior years recoverable through loss carrybacks	$ 10,103,801	$ -	$ 10,103,801
b.	Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation	200,751	-	200,751
1.	Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date	XXX	XXX	200,751
2.	Adjusted gross deferred tax assets allowed per limitation threshold	XXX	XXX	130,311,102
c.	Adjusted gross deferred tax assets offset by gross deferred tax liabilities	45,645	-	45,645
d.	Deferred tax assets admitted as the result of application of SSAP No. 101. Total	$ 10,350,197	$ -	$ 10,350,197

NOTES TO THE FINANCIAL STATEMENTS

	December 31, 2019		
	Ordinary	Capital	Total
a. Federal income taxes paid in prior years recoverable through loss carrybacks	$ 7,518,467	$ -	$ 7,518,467
b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation	166,131	-	166,131
1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date	XXX	XXX	166,131
2. Adjusted gross deferred tax assets allowed per limitation threshold	XXX	XXX	106,362,576
c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities	53,613	-	53,613
d. Deferred tax assets admitted as the result of application of SSAP No. 101. Total	$ 7,738,211	$ -	$ 7,738,211

	Change		
	Ordinary	Capital	Total
a. Federal income taxes paid in prior years recoverable through loss carrybacks	$ 2,585,334	$ -	$ 2,585,334
b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation	34,620	-	34,620
1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date	XXX	XXX	34,620
2. Adjusted gross deferred tax assets allowed per limitation threshold	XXX	XXX	23,948,526
c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities	(7,968)	-	(7,968)
d. Deferred tax assets admitted as the result of application of SSAP No. 101. Total	$ 2,611,986	$ -	$ 2,611,986

(3) The ratio percentage used to determine recovery period and threshold limitation amount was as follows:

	December 31, 2020	December 31, 2019
a. Ratio percentage used to determine recovery period and threshold limitation amount	633%	655%
b. Amount of adjusted capital and surplus used to determine recovery period and threshold limitation in 2 b.2 above	868,740,677	709,083,839

(4) The impact of tax planning strategies on adjusted gross DTAs and net admitted DTAs was as follows:

	December 31, 2020	
	Ordinary	Capital
a. Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage		
1. Adjusted gross DTAs amount from note 9A1(c)	$ 11,058,818	$ -
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	0.00%	0.00%
3. Net admitted adjusted gross DTAs amount from note 9A1(e)	$ 10,350,197	$ -
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies	0.00%	0.00%

	December 31, 2019	
	Ordinary	Capital
a. Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage		
1. Adjusted gross DTAs amount from note 9A1(c)	$ 8,271,943	$ -
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	0.00%	0.00%
3. Net admitted adjusted gross DTAs amount from note 9A1(e)	$ 7,738,211	$ -
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies	0.00%	0.00%

NOTES TO THE FINANCIAL STATEMENTS

	Change	
	Ordinary	Capital
a. Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage		
1. Adjusted gross DTAs amount from note 9A1(c)	$ 2,786,875	$ -
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	0.00%	0.00%
3. Net admitted adjusted gross DTAs amount from note 9A1(e)	$ 2,611,986	$ -
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies	0.00%	0.00%

b. Does the Company's tax planning strategies include the use of reinsurance? Yes [ ] No [X]

B. There are no temporary differences for which a DTL has not been established.

C. Current and deferred income taxes

(1) Current income taxes incurred consist of the following major components:

		December 31, 2020	December 31, 2019	Change
a.	Federal	$ 59,852,803	$ 37,596,118	$ 22,256,685
b.	Foreign	-	-	-
c.	Subtotal	59,852,803	37,596,118	22,256,685
d.	Federal income tax on net capital gains	2,200,822	640,341	1,560,481
e.	Utilization of capital loss carryforwards	-	-	-
f.	Other	(849)	(202,413)	201,564
g.	Federal and foreign income taxes incurred	$ 62,052,776	$ 38,034,046	$ 24,018,730

NOTES TO THE FINANCIAL STATEMENTS

(2–3) The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are as follows:

DTAs resulting from Book/Tax Differences in:

		December 31, 2020	December 31, 2019	Change
a.	Ordinary			
	1. Discounting of unpaid losses	$ 7,060,002	$ 5,828,439	$ 1,231,563
	2. Unearned premium reserve	152,148	61,544	90,604
	3. Policyholder reserves	-	-	-
	4. Investments and other	-	-	-
	5. Deferred acquisition costs	-	-	-
	6. Policyholder dividends accrual	-	-	-
	7. Fixed assets	-	-	-
	8. Compensation and benefit accruals	1,083	1,943	(860)
	9. Pension accruals	-	-	-
	10. Receivables – nonadmitted	-	-	-
	11. Net operating loss carry-forward	-	-	-
	12. Tax credit carry-forward	-	-	-
	13. Other	1,392	-	1,392
	14. Bad debts	1,730,308	1,030,636	699,672
	15. Accrued litigation	-	-	-
	16. CMS Rx reserve	476,107	76,603	399,504
	17. CMS risk corridor -ACA	-	-	-
	18. Medicare risk adjustment data	-	-	-
	19. Miscellaneous reserves	203,933	18,248	185,685
	20. Accrued lease	-	-	-
	21. Section 197 intangible	-	-	-
	22. Reinsurance fee	-	-	-
	23. Provider contracts	1,433,845	1,254,530	179,315
	24. Premium acquisition expense	-	-	-
	99. Subtotal	11,058,818	8,271,943	2,786,875
b.	Statutory valuation allowance adjustment	-	-	-
c.	Nonadmitted	(708,621)	(533,732)	(174,889)
d.	Admitted Ordinary DTAs	10,350,197	7,738,211	2,611,986
e.	Capital			
	1. Investments	1,350	13,378	(12,028)
	2. Net capital loss carry-forward	-	-	-
	3. Real estate	-	-	-
	4. Other	-	-	-
	99. Subtotal	1,350	13,378	(12,028)
f.	Statutory valuation allowance adjustment	(1,350)	(13,378)	12,028
g.	Nonadmitted	-	-	-
h.	Admitted capital DTAs	-	-	-
i.	Admitted DTAs	$ 10,350,197	$ 7,738,211	$ 2,611,986

NOTES TO THE FINANCIAL STATEMENTS

DTLs resulting from Book/Tax Differences in:

		December 31, 2020	December 31, 2019	Change
a.	Ordinary			
	1. Investments	$ -	$ -	$ -
	2. Fixed assets	-	-	-
	3. Deferred and uncollected premium	-	-	-
	4. Policyholder reserves/salvage & subrogation	-	-	-
	5. Other	-	-	-
	6. Premium acquisition reserve	(1,334)	(439)	(895)
	7. CMS Rx reserve	-	-	-
	8. Reserve transition adjustment	(44,311)	(53,174)	8,863
	99. Subtotal	(45,645)	(53,613)	7,968
b.	Capital			
	1. Investments	-	-	-
	2. Real estate	-	-	-
	3. Other	-	-	-
	99. Subtotal	-	-	-
c.	DTLs	$ (45,645)	$ (53,613)	$ 7,968
(4)	Net deferred tax asset/(liability)	$ 10,304,552	$ 7,684,598	$ 2,619,954

D. The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory Federal income tax rate to income before income taxes. The significant items causing this difference as of December 31, 2020 are as follows:

	Amount	Tax Effect	Effective Tax Rate
Income before taxes	$ 202,166,296	$ 42,454,922	21.00%
Tax-exempt interest	(1,057,255)	(222,024)	(0.12%)
Dividends received deduction	-	-	0.00%
Proration	264,314	55,506	0.03%
Meals & entertainment, lobbying expenses, etc.	447	94	0.00%
Statutory valuation allowance adjustment	-	-	0.00%
ACA Fee	91,320,689	19,177,345	9.49%
Change to nonadmitted assets & deferred tax true-up	(10,513,857)	(2,207,910)	(1.09%)
Other, including prior year true-up	-	-	0.00%
Total	$ 282,180,634	$ 59,257,933	29.31%
Federal income taxes incurred [expense/(benefit)]		$ 59,851,954	29.61%
Tax on capital gains/(losses)		2,200,822	1.09%
Change in net deferred income tax [charge/(benefit)]		(2,794,843)	(1.39%)
Total statutory income taxes		$ 59,257,933	29.31%

E. Operating loss and tax credit carry-forwards and protective tax deposits

(1) At December 31, 2020, the Company had no net operating loss carry-forwards.

At December 31, 2020, the Company had no capital loss carry-forwards.

At December 31, 2020, the Company had no AMT credit carry-forwards.

(2) The following table demonstrates the income tax expense for 2019 and 2020 that is available for the recoupment in the event of future net losses:

	Ordinary	Capital	Total
2019	$ 37,405,983	$ 640,341	$ 38,046,324
2020	59,852,803	2,200,822	62,053,625
Total	$ 97,258,786	$ 2,841,163	$ 100,099,949

(3) There are no deposits admitted under IRC § 6603.

NOTES TO THE FINANCIAL STATEMENTS

F. The Company is included in a consolidated federal income tax return with its parent Company, Humana Inc. The Company has a written agreement, approved by the Company's Board of Directors, which sets forth the manner in which the total combined federal income tax is allocated to each entity which is a party to the consolidation. Pursuant to this agreement, the Company has the enforceable right to be paid for any future net losses it may incur. The Company has no contingent income tax liabilities. The Company has not adjusted gross deferred tax assets due to changes in judgment about the realizability of the related deferred tax asset. The Company has no deposits under Section 6603 of the Internal Revenue Code.

HUMANA INC. AND SUBSIDIARIES INCLUDED IN 2020 CONSOLIDATED FEDERAL INCOME TAX RETURN

CALENDAR YEAR ENDED DECEMBER 31, 2020
AFFILIATIONS SCHEDULE

CORPORATE NAME AND EMPLOYER IDENTIFICATION NUMBER
THE ADDRESS OF EACH COMPANY IS: P. O. BOX 740026, LOUISVILLE, KY 40201

CORP. NO.	CORPORATION NAME	EMPLOYER IDENTIFICATION NUMBER
1	HUMANA INC.	61-0647538
2	154TH STREET MEDICAL PLAZA, INC.	65-0851053
3	516-526 WEST MAIN STREET CONDOMINIUM COUNCIL OF CO-OWNERS, INC.	20-5309363
4	54TH STREET MEDICAL PLAZA, INC.	65-0293220
5	ARCADIAN HEALTH PLAN, INC.	20-1001348
6	CAC MEDICAL CENTER HOLDINGS, INC.	30-0117876
7	CAC-FLORIDA MEDICAL CENTERS, LLC	26-0010657
8	CARENETWORK, INC.	39-1514846
9	CAREPLUS HEALTH PLANS, INC.	59-2598550
10	CARITEN HEALTH PLAN INC.	62-1579044
11	CHA HMO, INC.	61-1279717
12	COMPBENEFITS COMPANY	59-2531815
13	COMPBENEFITS CORPORATION	04-3185995
14	COMPBENEFITS DENTAL, INC.	36-3686002
15	COMPBENEFITS DIRECT, INC.	58-2228851
16	COMPBENEFITS INSURANCE COMPANY	74-2552026
17	COMPLEX CLINICAL MANAGEMENT, INC.	45-3713941
18	CONTINUCARE CORPORATION	59-2716023
19	CONTINUCARE MEDICAL MANAGEMENT, INC.	65-0791417
20	CONVIVA HEALTH MANAGEMENT, LLC (f/k/a TRANSCEND POPULATION HEALTH MANAGEMENT, LLC)	46-5329373
21	CONVIVA HEALTH MSO OF TEXAS, INC. (f/k/a PRIMARY CARE HOLDINGS, INC.)	46-1225873
22	CONVIVA MEDICAL CENTER MANAGEMENT OF TEXAS, P.A. (f/k/a PARTNERS IN PRIMARY CARE, P.A.)	47-1161014
23	DENTAL CARE PLUS MANAGEMENT, CORP.	36-3512545
24	DENTICARE, INC.	76-0039628
25	EAGLE RX HOLDCO, INC.	47-1407967
26	EAGLE RX, INC.	47-1416614
27	EDGE HEALTH MSO, INC.	84-2214810
28	EDGE HEALTH, P.C.	84-2752906
29	EMPHESYS INSURANCE COMPANY	31-0935772
30	EMPHESYS, INC.	61-1237697
31	ENCLARA PHARMACIA, INC.	23-3068914
32	FAMILY PHYSICIANS OF WINTER PARK, INC.	59-3164234
33	FPG ACQUISITION CORP.	81-3802918
34	FPG ACQUISITION HOLDINGS CORP.	81-3819187
35	FPG HOLDING COMPANY, LLC	32-0505460
36	GUIDANTRX, INC.	39-1789830
37	HARRIS, ROTHENBERG INTERNATIONAL, INC.	27-1649291
38	HEALTH VALUE MANAGEMENT, INC.	61-1223418
39	HUMANA ACTIVE OUTLOOK, INC.	20-4835394
40	HUMANA AT HOME (DALLAS), INC.	75-2739333
41	HUMANA AT HOME (HOUSTON), INC.	76-0537878
42	HUMANA AT HOME (SAN ANTONIO), INC.	01-0766084
43	HUMANA AT HOME (TLC), INC.	75-2600512
44	HUMANA AT HOME 1, INC.	65-0274594
45	HUMANA AT HOME, INC.	13-4036798

NOTES TO THE FINANCIAL STATEMENTS

46	HUMANA BENEFIT PLAN OF ILLINOIS, INC.	37-1326199
47	HUMANA BENEFIT PLAN OF SOUTH CAROLINA, INC.	84-3226630
48	HUMANA BENEFIT PLAN OF TEXAS, INC.	75-2043865
49	HUMANA DENTAL COMPANY	59-1843760
50	HUMANA DIGITAL HEALTH AND ANALYTICS PLATFORM SERVICES, INC.	80-0072760
51	HUMANA DIRECT CONTRACTING ENTITY, INC.	85-3099097
52	HUMANA EAP AND WORK-LIFE SERVICES OF CALIFORNIA, INC.	46-4912173
53	HUMANA EMPLOYERS HEALTH PLAN OF GEORGIA, INC.	58-2209549
54	HUMANA GOVERNMENT BUSINESS, INC.	61-1241225
55	HUMANA HEALTH BENEFIT PLAN OF LOUISIANA, INC.	72-1279235
56	HUMANA HEALTH COMPANY OF NEW YORK, INC.	26-2800286
57	HUMANA HEALTH INSURANCE COMPANY OF FLORIDA, INC.	61-1041514
58	HUMANA HEALTH PLAN OF CALIFORNIA, INC.	26-3473328
59	HUMANA HEALTH PLAN OF OHIO, INC.	31-1154200
60	HUMANA HEALTH PLAN OF TEXAS, INC.	61-0994632
61	HUMANA HEALTH PLAN, INC.	61-1013183
62	HUMANA HEALTHCARE RESEARCH, INC.	42-1575099
63	HUMANA HOME ADVANTAGE (TX), P.A.	81-0789608
64	HUMANA INNOVATION ENTERPRISES, INC.	61-1343791
65	HUMANA INSURANCE COMPANY	39-1263473
66	HUMANA INSURANCE COMPANY OF KENTUCKY	61-1311685
67	HUMANA INSURANCE COMPANY OF NEW YORK	20-2888723
68	HUMANA MARKETPOINT, INC.	61-1343508
69	HUMANA MEDICAL PLAN OF MICHIGAN, INC.	27-3991410
70	HUMANA MEDICAL PLAN OF PENNSYLVANIA, INC.	27-4460531
71	HUMANA MEDICAL PLAN OF UTAH, INC.	20-8411422
72	HUMANA MEDICAL PLAN, INC.	61-1103898
73	HUMANA PHARMACY SOLUTIONS, INC.	45-2254346
74	HUMANA PHARMACY, INC.	61-1316926
75	HUMANA REAL ESTATE COMPANY	20-1724127
76	HUMANA REGIONAL HEALTH PLAN, INC.	20-2036444
77	HUMANA VETERANS HEALTHCARE SERVICES, INC.	20-8418853
78	HUMANA WISCONSIN HEALTH ORGANIZATION INSURANCE CORPORATION	39-1525003
79	HUMANADENTAL INSURANCE COMPANY	39-0714280
80	HUMANADENTAL, INC.	61-1364005
81	HUMCO, INC.	61-1239538
82	HUM-e-FL, INC.	61-1383567
83	MANAGED CARE INDEMNITY, INC.	61-1232669
84	MEDICAL CARE CONSORTIUM INCORPORATED OF TEXAS	27-4379634
85	METCARE OF FLORIDA, INC.	65-0879131
86	METROPOLITAN HEALTH NETWORKS, INC.	65-0635748
87	PARTNERS IN INTEGRATED CARE, INC.	47-2905609
88	PARTNERS IN PRIMARY CARE (GA), P.C.	83-2624178
89	PARTNERS IN PRIMARY CARE (KS), P.A.	30-1236218
90	PARTNERS IN PRIMARY CARE (KS), P.C.	85-0733589
91	PARTNERS IN PRIMARY CARE (MO), P.C.	85-3676937
92	PARTNERS IN PRIMARY CARE (NC), P.C.	82-1926920
93	PARTNERS IN PRIMARY CARE (SC), P.C.	85-3577914
94	PBM HOLDING COMPANY	61-1340806
95	PBM PLUS MAIL SERVICE PHARMACY, LLC	20-2373204
96	PHP COMPANIES, INC.	62-1552091
97	PREFERRED HEALTH PARTNERSHIP, INC.	62-1250945
98	PRIMARY CARE MANAGEMENT, INC.	85-0858631
99	ROHC, LLC	75-2844854
100	SENIORBRIDGE FAMILY COMPANIES (FL), INC.	65-1096853
101	SENIORBRIDGE FAMILY COMPANIES (NY), INC.	36-4484443
102	TEXAS DENTAL PLANS, INC.	74-2352809
103	THE DENTAL CONCERN, INC.	52-1157181
104	TRANSCEND COMMUNITY PHYSICIAN NETWORK (AR), P.A.	47-2770181
105	TRANSCEND COMMUNITY PHYSICIAN NETWORK (KS), P.A.	47-2111323
106	TRANSCEND COMMUNITY PHYSICIAN NETWORK, P.C.	47-2750105

G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.

NOTES TO THE FINANCIAL STATEMENTS

10. Information Concerning Parent, Subsidiaries and Affiliates

A.-B. The Company has several management contracts with Humana Inc. and other related parties whereby the Company is provided with medical and executive management, information systems, claims processing, billing and enrollment, and telemarketing and other services as required by the Company. Management fees charged to operations for the years ended December 31, 2020 and 2019 were $554,467,058 and $423,633,092, respectively. As a part of this agreement, Humana Inc. makes cash disbursements on behalf of the Company which includes, but is not limited to, medical related items, general and administrative expenses, commissions and payroll. The Company continues to be primarily liable for any outstanding payments made on behalf of the Company, should Humana Inc. not be able to fulfill its obligations.

In the ordinary course of business, the Company also directly contracts with related parties to provide services that are routine in nature to its members. The administrative services, access fees, and cost of care services provided are determined within each individual agreement. The following table identifies the amount for the administrative services, access fees, and cost of care services provided by related parties for the years ended December 31, 2020 and 2019, which meet the disclosure requirements pursuant to SSAP No. 25, *Affiliate and Other Related Parties* (SSAP No. 25):

		2020		2019
SeniorBridge and Humana At Home	$	44,436,372	$	36,915,458
Transcend Population Health Management		(230,867)		72,227,676
Primary Care Holdings II, LLC		36,260,456		45,252,228
Total	$	80,465,961	$	154,395,362

In addition to the related parties above, the Company also has a contracted relationship with Humana Pharmacy Solutions, Inc. (HPS). HPS is responsible for designing pharmacy benefits, including defining member co-share responsibilities, determining formulary listings, contracting with retail pharmacies, confirming member eligibility, reviewing drug utilization, and processing claims for Humana entities. HPS has various contracts with pharmacy manufacturers to provide the Company with purchase discounts and volume rebates on certain prescription drugs utilized by its members. The Company has an agreement with HPS to collect pharmacy rebates on its behalf and remit them to the Company on a monthly basis. The Company had $1,504,533,053 and $1,125,459,316 of administrative service and prescription costs in 2020 and 2019, respectively, with HPS. The prescription costs included in fees paid to HPS are gross of the pharmacy rebates that the Company receives, see Footnote 28, and also includes payments for Medicare Part D claims that CMS reimburses the Company for through the Coverage Gap, Low Income and Reinsurance subsidies.

Included in the payments to HPS are also costs incurred from Humana Pharmacy, Inc. Humana Pharmacy, Inc. provides covered members with prescription services through use of the mail order as well as brick and mortar locations. These services are limited to maintenance medication prescription drug and allied services and supplies normally provided to the general public in the ordinary course of pharmacy business. The Company had $504,044,249 and $371,863,254 of prescription costs in 2020 and 2019, respectively, with Humana Pharmacy, Inc.

No dividends or returns of capital were paid by the Company as of December 31, 2020.

The Company received a $30,000,000 capital contribution from Humana Inc. on March 31, 2020.

C. (1) Detail of Material Related Party Transactions

Not Applicable.

(2) Detail of Material Related Party Transactions Involving Services

Not Applicable.

(3) Detail of Material Related Party Transactions Exchange of Assets and Liabilities

Not Applicable.

(4) Detail of Amounts Owed To/From a Related Party

Not Applicable.

D. At December 31, 2020, the Company reported $15,412,094 due to Humana Inc. Amounts due to or from parent are generally settled within 90 days.

E. Not Applicable.

F. Not Applicable.

G. All outstanding shares of the Company are owned by the Parent Company.

H. Not Applicable.

I. Not Applicable.

J. Not Applicable.

K. Not Applicable.

L. Not Applicable.

M. All SCA Investments

NOTES TO THE FINANCIAL STATEMENTS

Not Applicable.

N. Investment in Insurance SCA

Not Applicable.

O. SCA Loss Tracking

Not Applicable.

11. Debt

A. Debt Including Capital Notes

The Company has no debentures outstanding.

The Company has no capital notes outstanding.

The Company does not have any reverse repurchase agreements.

B. Federal Home Loan Bank (FHLB) Agreements

The Company does not have any FHLB agreements.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A.-D. Defined Benefit Plans

Not Applicable.

E. Defined Contribution Plans

Not Applicable.

F. Multiemployer Plans

Not Applicable.

G. Consolidated/Holding Company Plans

The Company employees are eligible to participate in the Humana Retirement and Savings Plan ("the Plan"), a defined contribution plan, sponsored by Humana Inc. The Plan maintains two accounts, the Savings Account and the Retirement Account.

Humana Inc.'s total contributions paid to the Savings and Retirement accounts of the Humana Retirement Savings Plan were $233,856,665 and $219,268,247 for the years ended December 31, 2020 and 2019, respectively. Of these contributions, the Company contributed $8,011 and $22,091 during 2020 and 2019, respectively. As of December 31, 2020 and 2019, the fair market value of the Humana Retirement Savings Plan's assets was $6,280,051,531 and $5,344,599,370, respectively.

H. Postemployment Benefits and Compensated Absences

Not Applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not Applicable.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

A. The Company has $16.667 par value common stock with 60,000 shares authorized and 60,000 shares issued and 60,000 outstanding. All shares are common stock shares.

B. The Company has no preferred stock outstanding.

C.-E. Dividends and returns of capital to shareholders are noncumulative and are paid as determined by the Board of Directors. In accordance with the Office statutes, the maximum amount which can be paid by the Company to shareholders without prior approval by the Office is the lesser of 10% of total surplus, or the greater of net operating gain for the calendar year preceding the dividend or for the 3 calendar years preceding the dividend less dividends paid for the most recent 2 of those calendar years. All ordinary dividends are limited to available and accumulated surplus funds. Based on these restrictions, the Company could have paid a maximum dividend or return of capital to shareholders of approximately $71,670,000 in 2020 without prior regulatory approval.

Within the limitations above, there are no restrictions placed on the portion of Company profits that may be paid as ordinary dividends to stockholders.

No dividends or returns of capital were paid by the Company as of December 31, 2020.

F. There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.

NOTES TO THE FINANCIAL STATEMENTS

G. Not Applicable.

H. Not Applicable.

I. Changes in balances of special surplus funds from the prior year is due to the health insurance industry fee having been permanently repealed beginning calendar year 2021.

J. The portion of unassigned funds (surplus) represented or reduced by cumulative unrealized gains and losses is $57,176.

K. Not Applicable.

L. Not Applicable.

M. Not Applicable.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

Not Applicable.

B. Assessments

Not Applicable.

C. Gain Contingencies

Not Applicable.

D. Claims related extra contractual obligation and bad faith losses stemming from lawsuits

Not Applicable.

E. Joint and Several Liabilities

Not Applicable.

F. All Other Contingencies

During the ordinary course of business, the Company is subject to pending and threatened legal actions. Management of the Company does not believe that any of these actions will have a material adverse effect on the Company's surplus, results of operations or cash flows. However, the likelihood or outcome of current or future legal proceedings cannot be accurately predicted, and they could adversely affect the Company's surplus, results of operations and cash flows.

The Company is not aware of any other material contingent liabilities as of December 31, 2020.

15. Leases

Not Applicable.

16. Information about Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company has no investment in Financial Instruments with Off-Balance Sheet Risk or Concentrations of Credit Risk.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not Applicable.

B. Transfer and Servicing of Financial Assets

Not Applicable.

C. Wash Sales

Not Applicable.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. ASO Plans

Not Applicable.

B. ASC Plans

Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract

(1) The Company records no revenue explicitly attributable to the cost share and reinsurance components of its Medicare or other similarly structured cost based reimbursement contracts.

(2) As of December 31, 2020, the Company has recorded a receivable from CMS of $33,442,902 related to the cost share and reinsurance components of administered Medicare products. The Company does not have any receivables greater than 10% of the Company's accounts receivable from uninsured accident and health plans or $10,000.

(3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare or other similarly structured cost based reimbursement contracts, the Company has recorded no allowances and reserves for adjustment of recorded revenues and receivables.

(4) The Company has made no adjustment to revenue resulting from audit of receivables related to revenues recorded in the prior period.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

Not Applicable.

20. Fair Value Measurements

A. (1) The fair value of financial assets at December 31, 2020 were as follows:

	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Total
a. Assets at fair value					
Bonds					
U.S. governments	$ -	$ -	$ -	$ -	$ -
Tax-exempt municipal	-	-	-	-	-
Residential mortgage-backed	-	-	-	-	-
Corporate debt securities	-	3,059,328	-	-	3,059,328
Total bonds	-	3,059,328	-	-	3,059,328
Total assets at fair value/NAV	$ -	$ 3,059,328	$ -	$ -	$ 3,059,328
b. Liabilities at fair value	$ -	$ -	$ -	$ -	$ -
Total liabilities at fair value	$ -	$ -	$ -	$ -	$ -

The Company reports transfers between Level 1 and Level 2 of the fair value hierarchy levels at the end of the reporting period. There were no transfers between Level 1 and Level 2 of the fair value hierarchy between December 31, 2019 and December 31, 2020.

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

Not Applicable.

(3) The Company reports transfers into or out of Level 3 of the fair value hierarchy levels at the end of the reporting period. There were no transfers into or out of Level 3 of the fair value hierarchy levels between December 31, 2019 and December 31, 2020.

(4) Fair value of actively traded debt securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. The Company generally obtains one quoted price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates and prepayment speeds. The Company is responsible for the determination of fair value and as such, the Company performs analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. The Company's analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by the Company's third party investment advisor. Based on the Company's internal price verification procedures and review of fair value methodology documentation provided by the third party pricing service, there were no material adjustments to the prices obtained from the third party pricing service during the year ended December 31, 2020.

(5) Derivative Fair Values

Not Applicable.

B. Other Fair Value Disclosures

Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

C. Fair Values for All Financial Instruments by Levels 1, 2 and 3

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, short-term investments and cash equivalents	$ 1,230,979,412	$ 1,190,644,735	$ 198,659,038	$ 1,032,320,374	$ -	$ -	$ -

D. Financial Instruments for which Not Practicable to Estimate Fair Values

Not Applicable.

21. Other Items

A. Extraordinary Items

The emergence and spread of the novel coronavirus, or COVID-19, has impacted the Company's business. Beginning in the second half of March 2020, the implementation of stay-at-home and physical distancing orders and other restrictions on movement and economic activity resulted in the temporary deferral of non-essential care and significant reduction in hospital admissions and overall healthcare system utilization during April 2020. Non-COVID utilization then began to increase during May and June 2020 and continued to rebound throughout the third quarter and early in the fourth quarter of 2020. Then, in the latter half of November and accelerating throughout the month of December, the Company experienced a significant increase in COVID-19 admissions in nearly all of the markets in which it operates across the Company's lines of business resulting in higher COVID-19 treatment and testing costs.

B. Troubled Debt Restructuring: Debtors

Not Applicable.

C. Other Disclosures and Unusual Items

Not Applicable.

D. Business Interruption Insurance Recoveries

Not Applicable.

E. State Transferable and Non-transferable Tax Credits

Not Applicable.

F. Subprime Mortgage Related Risk Exposure

(1) The Company consults with its external investment managers to assess its subprime mortgage related risk exposure. Certain characteristics are utilized to determine if a mortgage-backed security has subprime exposure. The main characteristics reviewed when determining this are the collateral and structure of the security, the loan purpose, loan documentation, occupancy, geographical location, loan size and type. Subprime mortgage borrowers typically have lower credit scores, lower loan balances and higher loan-to-values than other conforming loans. Management's practices include reviewing quantitative and qualitative credit models that analyze loan-level collateral composition, historical underwriter performance trends, the impact of macroeconomic factors, and issuer risks; as well as reviewing the estimation of security cash flows and monthly model calibrations.

(2) Direct exposure through investments in sub-prime mortgage loans.

The Company has no direct exposure through investment to sub-prime mortgage loans.

(3) Direct exposure through other investments:

a. Residential mortgage backed securities – No substantial exposure noted.
b. Commercial mortgage backed securities – No substantial exposure noted.
c. Collateralized debt obligations – No substantial exposure noted.
d. Structured securities – No substantial exposure noted.
e. Equity investment in SCAs – No substantial exposure noted.
f. Other assets – No substantial exposure noted.
g. Total – No substantial exposure noted.

(4) Underwriting exposure to sub-prime mortgage risk through Mortgage Guaranty coverage, Financial Guaranty coverage, Directors and Officers liability coverage, or Errors and Omissions liability coverage.

The Company does not have sub-prime mortgage risk.

Classification of mortgage related securities is primarily based on information from outside data services, including rating agency actions. When considering our exposure, the Company evaluated the percentage of full documentation loans, percent of owner occupied properties, FICO scores, average margin for ARM loans, percent of loans with prepayment penalties, the existence of non-traditional underwriting standards, among other factors.

G. Retained Assets

Not Applicable.

H. Insurance Linked Securities

NOTES TO THE FINANCIAL STATEMENTS

Not Applicable.

22. Events Subsequent

On January 1, 2020 the Company was subject to the annual fee under Section 9010 of the Federal Affordable Care Act (ACA). The Consolidated Appropriations Act enacted on December 18, 2015, included a one-time one year suspension in 2017 of the health insurer fee. The Continuing Resolution bill, H.R. 195, enacted on January 22, 2018, included a one year suspension in 2019 of the health insurer fee, but the fee has resumed for calendar year 2020. A segregation was recorded within special surplus for the annual health insurance industry fee related to the 2019 data year for the 2020 fee. This annual fee was allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of health insurance for any U.S. health risk that was written during the preceding calendar year. The 2020 fee was paid September 30, 2020. The impact of the annual health insurance industry fee on the Company's operations as of December 31, 2020 and 2019 were as follows:

		Current Year	Prior Year
A.	Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the federal Affordable Care Act (YES/NO)?	No	
B.	ACA fee assessment payable for the upcoming year	$ -	$ 86,545,504
C.	ACA fee assessment paid	$ 91,320,689	$ -
D.	Premiums written subject to ACA 9010 assessment	$ -	$ 4,353,829,769
E.	Total Adjusted Capital before surplus adjustment (Five-Year Historical Line 14)	$ 879,045,229	$ 630,222,934
F.	Total Adjusted Capital after surplus adjustment (Five-Year Historical Line 14 minus 22B above)	$ 879,045,229	$ 630,222,934
G.	Authorized Control Level (Five-Year Historical Line 15)	$ 137,325,207	$ 108,214,412
H.	Would reporting the ACA assessment as of December 31, 2020, have triggered an RBC action level (YES/NO)	No	

The further consolidated Appropriations Act 2020, enacted on December 20, 2019, permanently repealed the health insurance industry fee for calendar years 2021 and thereafter.

The Company is not aware of any events or transactions occurring subsequent to the close of the books for this statement which may have a material effect on its financial condition. Subsequent events have been considered through February 25, 2021 for the Statutory Statement issued on February 25, 2021.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 – General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10.0 percent or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

Yes ( ) No (X)

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10.0 percent or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes ( ) No (X)

Section 2 – Ceded Reinsurance Report – Part A

(1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes ( ) No (X)

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes ( ) No (X)

Section 3 – Ceded Reinsurance Report – Part B

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business

NOTES TO THE FINANCIAL STATEMENTS

reinsured in making this estimate. $0

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?

Yes ( ) No (X)

B. Uncollectible Reinsurance

Not Applicable.

C. Commutation of Ceded Reinsurance

Not Applicable.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation

Not Applicable.

24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

A. The Company estimates accrued retrospective premium adjustments for its Medicare business through a mathematical approach using an algorithm based upon settlement procedures defined by contracts with CMS.

B. The Company records accrued retrospective premium as an adjustment to earned premiums.

C. The amount of net premiums written by the Company at December 31, 2020 that are subject to retrospective rating features was $5,513,801,635, or 100.00% of the total net premiums written. No other net premiums written by the Company are subject to retrospective rating features.

D. Medical loss ratio rebates required pursuant to the Public Health Service Act

Not Applicable.

E. Risk Sharing Provisions of the Affordable Care Act

Not Applicable.

25. Change in Incurred Claims and Claim Adjustment Expenses

Benefits and loss adjustment expenses payable, net of health care receivables, as of December 31, 2019 were $363,487,554. As of December 31, 2020, $357,364,302 has been paid for incurred claims and claim adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now $8,451,069 as a result of re-estimation of unpaid claims and claim adjustment expenses. Therefore, there has been a $2,327,818 unfavorable prior-year development since December 31, 2019. The increase is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased as additional information becomes known regarding individual claims. Included in this increase, the Company experienced $2,327,818 of unfavorable prior year claim development on retrospectively rated policies. However, the business to which it relates is subject to premium adjustments.

26. Intercompany Pooling Arrangements

Not Applicable.

27. Structured Settlements

The Company has no structured settlements.

NOTES TO THE FINANCIAL STATEMENTS

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

Quarter	Estimate Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More than 181 Days after Billing
12/31/2020	$ 89,378,981	$ 89,378,981	$ -	$ -	$ -
9/30/2020	120,547,639	120,547,639	119,638,771	-	-
6/30/2020	134,630,331	134,630,331	133,427,752	1,119,304	-
3/31/2020	98,641,596	98,641,596	96,236,730	2,404,866	-
12/31/2019	73,283,351	73,283,351	72,896,071	-	-
9/30/2019	81,082,048	81,082,048	80,521,374	168,994	391,680
6/30/2019	119,518,755	119,518,755	118,016,591	388,230	1,113,934
3/31/2019	78,040,458	78,040,458	77,296,766	-	743,692
12/31/2018	56,761,098	56,761,098	56,106,624	273,710	160,334
9/30/2018	68,353,073	68,353,073	68,123,613	229,460	-
6/30/2018	82,118,478	82,118,478	81,769,886	348,592	-
3/31/2018	50,657,583	50,657,583	50,657,583	-	-

B. Risk Sharing Receivables

Not Applicable.

29. Participating Policies

The Company has no participating policies.

30. Premium Deficiency Reserves

Not Applicable.

31. Anticipated Salvage and Subrogation

Not Applicable.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES
GENERAL

1.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer? ..... Yes [X] No [ ]
If yes, complete Schedule Y, Parts 1, 1A and 2

1.2 If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent, or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations? ..... Yes [X] No [ ] N/A [ ]

1.3 State Regulating? ..... Washington

1.4 Is the reporting entity publicly traded or a member of a publicly traded group? ..... Yes [X] No [ ]

1.5 If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group. 0000049071

2.1 Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity? ..... Yes [ ] No [X]

2.2 If yes, date of change: .....

3.1 State as of what date the latest financial examination of the reporting entity was made or is being made. 12/31/2020

3.2 State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released. 03/31/2019

3.3 State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date). 12/12/2019

3.4 By what department or departments?
Washington Department of Insurance/California Department of Managed Healthcare .....

3.5 Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments? ..... Yes [X] No [ ] N/A [ ]

3.6 Have all of the recommendations within the latest financial examination report been complied with? ..... Yes [X] No [ ] N/A [ ]

4.1 During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.11 sales of new business? ..... Yes [ ] No [X]
4.12 renewals? ..... Yes [ ] No [X]

4.2 During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate, receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.21 sales of new business? ..... Yes [ ] No [X]
4.22 renewals? ..... Yes [ ] No [X]

5.1 Has the reporting entity been a party to a merger or consolidation during the period covered by this statement? ..... Yes [ ] No [X]
If yes, complete and file the merger history data file with the NAIC.

5.2 If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.

1 Name of Entity	2 NAIC Company Code	3 State of Domicile

6.1 Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period? ..... Yes [ ] No [X]

6.2 If yes, give full information:
.....

7.1 Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity? ..... Yes [ ] No [X]

7.2 If yes,
7.21 State the percentage of foreign control; ..... 0.0 %
7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the entity is a mutual or reciprocal, the nationality of its manager or attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation or government, manager or attorney in fact).

1 Nationality	2 Type of Entity

GENERAL INTERROGATORIES

8.1 Is the company a subsidiary of a bank holding company regulated by the Federal Reserve Board? ..... Yes [ ] No [X]

8.2 If response to 8.1 is yes, please identify the name of the bank holding company.

Not Applicable. .....

8.3 Is the company affiliated with one or more banks, thrifts or securities firms? ..... Yes [ ] No [X]

8.4 If response to 8.3 is yes, please provide below the names and location (city and state of the main office) of any affiliates regulated by a federal regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.

1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC
.....	.....	.....	.....	.....	.....

9. What is the name and address of the independent certified public accountant or accounting firm retained to conduct the annual audit?

PricewaterhouseCoopers LLC, 500 West Main Street, Suite 1800, Louisville, Kentucky 40202-4264

10.1 Has the insurer been granted any exemptions to the prohibited non-audit services provided by the certified independent public accountant requirements as allowed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Rule), or substantially similar state law or regulation? ..... Yes [ ] No [X]

10.2 If the response to 10.1 is yes, provide information related to this exemption:

.....

10.3 Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation? ..... Yes [ ] No [X]

10.4 If the response to 10.3 is yes, provide information related to this exemption:

.....

10.5 Has the reporting entity established an Audit Committee in compliance with the domiciliary state insurance laws? ..... Yes [X] No [ ] N/A [ ]

10.6 If the response to 10.5 is no or n/a, please explain

.....

11. What is the name, address and affiliation (officer/employee of the reporting entity or actuary/consultant associated with an actuarial consulting firm) of the individual providing the statement of actuarial opinion/certification?

Drew Besendorf, Appointed Actuary, 500 West Main Street, Louisville, KY 40202 .....

12.1 Does the reporting entity own any securities of a real estate holding company or otherwise hold real estate indirectly? ..... Yes [ ] No [X]

12.11 Name of real estate holding company .....

12.12 Number of parcels involved 0

12.13 Total book/adjusted carrying value ..... $ 0

12.2 If, yes provide explanation:

.....

13. **FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES ONLY:**

13.1 What changes have been made during the year in the United States manager or the United States trustees of the reporting entity?

Not Applicable. .....

13.2 Does this statement contain all business transacted for the reporting entity through its United States Branch on risks wherever located? ..... Yes [ ] No [ ]

13.3 Have there been any changes made to any of the trust indentures during the year? ..... Yes [ ] No [ ]

13.4 If answer to (13.3) is yes, has the domiciliary or entry state approved the changes? ..... Yes [ ] No [ ] N/A [X]

14.1 Are the senior officers (principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) of the reporting entity subject to a code of ethics, which includes the following standards? ..... Yes [X] No [ ]

a. Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

b. Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the reporting entity;

c. Compliance with applicable governmental laws, rules and regulations;

d. The prompt internal reporting of violations to an appropriate person or persons identified in the code; and

e. Accountability for adherence to the code.

14.11 If the response to 14.1 is No, please explain:

.....

14.2 Has the code of ethics for senior managers been amended? ..... Yes [X] No [ ]

14.21 If the response to 14.2 is yes, provide information related to amendment(s).

Ethics Every Day was amended in June 2020 to update content based on operational and regulatory changes, clarify content where necessary and perform general document maintenance. .....

14.3 Have any provisions of the code of ethics been waived for any of the specified officers? ..... Yes [ ] No [X]

14.31 If the response to 14.3 is yes, provide the nature of any waiver(s).

.....

GENERAL INTERROGATORIES

15.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List? ..... Yes [ ] No [X]

15.2 If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered.

1 American Bankers Association (ABA) Routing Number	2 Issuing or Confirming Bank Name	3 Circumstances That Can Trigger the Letter of Credit	4 Amount

BOARD OF DIRECTORS

16. Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? ..... Yes [X] No [ ]

17. Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? ..... Yes [X] No [ ]

18. Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict with the official duties of such person? ..... Yes [X] No [ ]

FINANCIAL

19. Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? ..... Yes [ ] No [X]

20.1 Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans):

20.11 To directors or other officers ..... $ 0

20.12 To stockholders not officers ..... $ 0

20.13 Trustees, supreme or grand (Fraternal Only) ..... $ 0

20.2 Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans):

20.21 To directors or other officers ..... $ 0

20.22 To stockholders not officers ..... $ 0

20.23 Trustees, supreme or grand (Fraternal Only) ..... $ 0

21.1 Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? ..... Yes [ ] No [X]

21.2 If yes, state the amount thereof at December 31 of the current year:

21.21 Rented from others ..... $ 0

21.22 Borrowed from others ..... $ 0

21.23 Leased from others ..... $ 0

21.24 Other ..... $ 0

22.1 Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? ..... Yes [ ] No [X]

22.2 If answer is yes:

22.21 Amount paid as losses or risk adjustment $ 0

22.22 Amount paid as expenses ..... $ 0

22.23 Other amounts paid ..... $ 0

23.1 Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? ..... Yes [ ] No [X]

23.2 If yes, indicate any amounts receivable from parent included in the Page 2 amount: ..... $ 0

INVESTMENT

24.01 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in the actual possession of the reporting entity on said date? (other than securities lending programs addressed in 24.03) ..... Yes [X] No [ ]

24.02 If no, give full and complete information relating thereto

.....

24.03 For securities lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided)
N/A .....

24.04 For the reporting entity's securities lending program, report amount of collateral for conforming programs as outlined in the Risk-Based Capital Instructions. ..... $ 0

24.05 For the reporting entity's securities lending program, report amount of collateral for other programs. ..... $ 0

24.06 Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract? ..... Yes [ ] No [ ] N/A [X]

24.07 Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%? ..... Yes [ ] No [ ] N/A [X]

24.08 Does the reporting entity or the reporting entity 's securities lending agent utilize the Master Securities lending Agreement (MSLA) to conduct securities lending? ..... Yes [ ] No [ ] N/A [X]

GENERAL INTERROGATORIES

24.09 For the reporting entity's securities lending program state the amount of the following as of December 31 of the current year:

24.091	Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2.	$ 0
24.092	Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2	$ 0
24.093	Total payable for securities lending reported on the liability page.	$ 0

25.1 Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity, or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 24.03). Yes [X] No [ ]

25.2 If yes, state the amount thereof at December 31 of the current year:

25.21	Subject to repurchase agreements	$ 0
25.22	Subject to reverse repurchase agreements	$ 0
25.23	Subject to dollar repurchase agreements	$ 0
25.24	Subject to reverse dollar repurchase agreements	$ 0
25.25	Placed under option agreements	$ 0
25.26	Letter stock or securities restricted as to sale - excluding FHLB Capital Stock	$ 0
25.27	FHLB Capital Stock	$ 0
25.28	On deposit with states	$ 11,601,925
25.29	On deposit with other regulatory bodies	$ 0
25.30	Pledged as collateral - excluding collateral pledged to an FHLB	$ 0
25.31	Pledged as collateral to FHLB - including assets backing funding agreements	$ 0
25.32	Other	$ 0

25.3 For category (25.26) provide the following:

1 Nature of Restriction	2 Description	3 Amount

26.1 Does the reporting entity have any hedging transactions reported on Schedule DB? Yes [ ] No [X]

26.2 If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? Yes [ ] No [ ] N/A [X]
If no, attach a description with this statement.

LINES 26.3 through 26.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY:

26.3 Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? Yes [ ] No [ ]

26.4 If the response to 26.3 is YES, does the reporting entity utilize:

26.41	Special accounting provision of SSAP No. 108	Yes [ ] No [ ]
26.42	Permitted accounting practice	Yes [ ] No [ ]
26.43	Other accounting guidance	Yes [ ] No [ ]

26.5 By responding YES to 26.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following: Yes [ ] No [ ]

- The reporting entity has obtained explicit approval from the domiciliary state.
- Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21.
- Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment of VM-21 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount.
- Financial Officer Certification has been obtained which indicates that the hedging strategy meets the definition of a Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts.

27.1 Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity? Yes [ ] No [X]

27.2 If yes, state the amount thereof at December 31 of the current year. $ 0

28. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC Financial Condition Examiners Handbook? Yes [X] No [ ]

28.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

1 Name of Custodian(s)	2 Custodian's Address
JP Morgan Chase	4 Metro Tech Center, 6th Floor, Mail Code: NY1-C512, Brooklyn, NY 11245, Attn: Charline Ottley

GENERAL INTERROGATORIES

28.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1 Name(s)	2 Location(s)	3 Complete Explanation(s)

28.03 Have there been any changes, including name changes, in the custodian(s) identified in 28.01 during the current year? ..... Yes [ ] No [X]

28.04 If yes, give full and complete information relating thereto:

1 Old Custodian	2 New Custodian	3 Date of Change	4 Reason

28.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["…that have access to the investment accounts"; "…handle securities"]

1 Name of Firm or Individual	2 Affiliation
BLACKROCK FINANCIAL MANAGEMENT, INC	U
W. Mark Preston	I

28.0597 For those firms/individuals listed in the table for Question 28.05, do any firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") manage more than 10% of the reporting entity's invested assets? ..... Yes [X] No [ ]

28.0598 For firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") listed in the table for Question 28.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets? ..... Yes [X] No [ ]

28.06 For those firms or individuals listed in the table for 28.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1 Central Registration Depository Number	2 Name of Firm or Individual	3 Legal Entity Identifier (LEI)	4 Registered With	5 Investment Management Agreement (IMA) Filed
107105	BLACKROCK FINANCIAL MANAGEMENT, INC	549300LVXYIVJKE13M84	The SEC	DS

29.1 Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? ..... Yes [ ] No [X]

29.2 If yes, complete the following schedule:

1 CUSIP #	2 Name of Mutual Fund	3 Book/Adjusted Carrying Value
29.2999 - Total		0

29.3 For each mutual fund listed in the table above, complete the following schedule:

1 Name of Mutual Fund (from above table)	2 Name of Significant Holding of the Mutual Fund	3 Amount of Mutual Fund's Book/Adjusted Carrying Value Attributable to the Holding	4 Date of Valuation

GENERAL INTERROGATORIES

30. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1 Statement (Admitted) Value	2 Fair Value	3 Excess of Statement over Fair Value (-), or Fair Value over Statement (+)
30.1 Bonds	1,190,563,300	1,230,898,621	40,335,321
30.2 Preferred stocks	0	0	0
30.3 Totals	1,190,563,300	1,230,898,621	40,335,321

30.4 Describe the sources or methods utilized in determining the fair values:

Fair value of actively traded debt and equity securities are based on quoted market prices.Fair value of inactively traded debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates using either a market or income valuation.

31.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D? Yes [ ] No [X]

31.2 If the answer to 31.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source? Yes [ ] No [ ]

31.3 If the answer to 31.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:

32.1 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? Yes [X] No [ ]

32.2 If no, list exceptions:

33. By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:
    a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.
    b. Issuer or obligor is current on all contracted interest and principal payments.
    c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.

    Has the reporting entity self-designated 5GI securities? Yes [ ] No [X]

34. By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:
    a. The security was purchased prior to January 1, 2018.
    b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.
    c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.
    d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.

    Has the reporting entity self-designated PLGI securities? Yes [ ] No [X]

35. By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:
    a. The shares were purchased prior to January 1, 2019.
    b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.
    c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.
    d. The fund only or predominantly holds bonds in its portfolio.
    e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.
    f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.

    Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria? Yes [ ] No [X]

36. By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:
    a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.
    b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.
    c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.
    d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 36.a - 36.c are reported as long-term investments.

    Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria? Yes [ ] No [ ] N/A [X]

GENERAL INTERROGATORIES

OTHER

37.1 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any? ..... $ 0

37.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations and statistical or rating bureaus during the period covered by this statement.

1 Name	2 Amount Paid

38.1 Amount of payments for legal expenses, if any? ..... $ 6,049

38.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1 Name	2 Amount Paid
FALKENBERG IVES LLP	6,049

39.1 Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of government, if any? ..... $ 0

39.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers or departments of government during the period covered by this statement.

1 Name	2 Amount Paid

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1 Does the reporting entity have any direct Medicare Supplement Insurance in force? Yes [ ] No [X]

1.2 If yes, indicate premium earned on U.S. business only. $ 0

1.3 What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit? $ 0

1.31 Reason for excluding

1.4 Indicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above $ 0

1.5 Indicate total incurred claims on all Medicare Supplement Insurance. $ 0

1.6 Individual policies:

Most current three years:	
1.61 Total premium earned	$ 0
1.62 Total incurred claims	$ 0
1.63 Number of covered lives	0
All years prior to most current three years:	
1.64 Total premium earned	$ 0
1.65 Total incurred claims	$ 0
1.66 Number of covered lives	0

1.7 Group policies:

Most current three years:	
1.71 Total premium earned	$ 0
1.72 Total incurred claims	$ 0
1.73 Number of covered lives	0
All years prior to most current three years:	
1.74 Total premium earned	$ 0
1.75 Total incurred claims	$ 0
1.76 Number of covered lives	0

2. Health Test:

		1 Current Year	2 Prior Year
2.1	Premium Numerator	5,513,801,635	4,345,827,532
2.2	Premium Denominator	5,513,801,635	4,345,827,532
2.3	Premium Ratio (2.1/2.2)	1.000	1.000
2.4	Reserve Numerator	671,426,767	454,465,622
2.5	Reserve Denominator	671,426,767	454,465,622
2.6	Reserve Ratio (2.4/2.5)	1.000	1.000

3.1 Has the reporting entity received any endowment or gift from contracting hospitals, physicians, dentists, or others that is agreed will be returned when, as and if the earnings of the reporting entity permits? Yes [ ] No [X]

3.2 If yes, give particulars:

4.1 Have copies of all agreements stating the period and nature of hospitals', physicians', and dentists' care offered to subscribers and dependents been filed with the appropriate regulatory agency? Yes [X] No [ ]

4.2 If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these agreements include additional benefits offered? Yes [ ] No [X]

5.1 Does the reporting entity have stop-loss reinsurance? Yes [ ] No [X]

5.2 If no, explain:
Stop-Loss Reinsurance is not required

5.3 Maximum retained risk (see instructions)

5.31 Comprehensive Medical	$ 0
5.32 Medical Only	$ 0
5.33 Medicare Supplement	$ 0
5.34 Dental & Vision	$ 0
5.35 Other Limited Benefit Plan	$ 0
5.36 Other	$ 0

6. Describe arrangement which the reporting entity may have to protect subscribers and their dependents against the risk of insolvency including hold harmless provisions, conversion privileges with other carriers, agreements with providers to continue rendering services, and any other agreements:
Provider contracts include hold harmless and continuation of benefits provisions. Insurer has an indemnity agreement with the parent company.

7.1 Does the reporting entity set up its claim liability for provider services on a service date basis? Yes [X] No [ ]

7.2 If no, give details

8. Provide the following information regarding participating providers:

8.1 Number of providers at start of reporting year	186,866
8.2 Number of providers at end of reporting year	196,098

9.1 Does the reporting entity have business subject to premium rate guarantees? Yes [X] No [ ]

9.2 If yes, direct premium earned:

9.21 Business with rate guarantees between 15-36 months	$ 428,998
9.22 Business with rate guarantees over 36 months	$ 0

GENERAL INTERROGATORIES

10.1 Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts? ..... Yes [X] No [ ]

10.2 If yes:

10.21 Maximum amount payable bonuses	$	91,212,103
10.22 Amount actually paid for year bonuses	$	52,303,537
10.23 Maximum amount payable withholds	$	0
10.24 Amount actually paid for year withholds	$	0

11.1 Is the reporting entity organized as:

11.12 A Medical Group/Staff Model, ...	Yes [ ] No [X]
11.13 An Individual Practice Association (IPA), or, .	Yes [ ] No [X]
11.14 A Mixed Model (combination of above)?	Yes [ ] No [X]

11.2 Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirements? ..... Yes [X] No [ ]

11.3 If yes, show the name of the state requiring such minimum capital and surplus. ..... Washington (DOI dictated requirement)

11.4 If yes, show the amount required. ..... $ 689,225,204

11.5 Is this amount included as part of a contingency reserve in stockholder's equity? ..... Yes [ ] No [X]

11.6 If the amount is calculated, show the calculation

See RBC calculation or state regulation.

12. List service areas in which reporting entity is licensed to operate:

1 Name of Service Area
AL - Autauga, Baldwin, Bibb, Cherokee, Clarke, Colbert, Cullman, Elmore, Escambia, Etowah, Fayette, Jackson, Jefferson, Lauderdale, Lawrence, Limestone, Madison, Marshall, Mobile, Monroe, Montgomery, Morgan, Pike, Shelby, Tuscaloosa, Walker, Washington
AZ - Coconino, Mohave, Yavapai
AR - Baxter, Benton, Boone, Carroll, Clark, Cleburne, Conway, Craighead, Crawford, Crittenden, Faulkner, Franklin, Fulton, Garland, Grant, Greene, Hempstead, Hot Spring, Howard, Independence, Izard, Jefferson, Johnson, Lawrence, Little River, Lonoke, Madison, Marion, Miller, Nevada, Perry, Pike, Poinsett, Polk, Pope, Prairie, Pulaski, Randolph, Saline, Searcy, Sebastian, Sevier, Sharp, Union, Van Buren, Washington, White
CA - Alameda, Butte, Calaveras, Contra Costa, Fresno, Kern, Kings, Lake, Los Angeles, Madera, Marin, Mendocino, Merced, Monterey, Orange, Placer, Riverside, Sacramento, San Bernardino, San Diego, San Francisco, San Joaquin, San Luis Obispo, San Mateo, Santa Barbara, Santa Clara, Santa Cruz, Shasta, Solano, Sonoma, Stanislaus, Tehama, Tulare, Tuolumne, Ventura, Yolo
ID - Ada, Bonner, Canyon, Kootenai, Payette
IN - Adams, Allen, Boone, Clark, De Kalb, Delaware, Elkhart, Floyd, Gibson, Grant, Hamilton, Hancock, Hendricks, Howard, Huntington, Johnson, Kosciusko, La Grange, La Porte, Lake, Madison, Marion, Marshall, Monroe, Montgomery, Morgan, Noble, Posey, St. Joseph, Tippecanoe, Vanderburgh, Wabash, Warrick, Wells, Whitley
KY - Statewide
ME - Statewide
MO - Barry, Cedar, Christian, Dade, Dallas, Douglas, Greene, Jasper, Laclede, Lawrence, McDonald, Newton, Polk, Pulaski, Stone, Taney, Webster, Wright
NE - Cass, Dakota, Dodge, Douglas, Lancaster, Sarpy, Saunders, Washington
NH - Belknap, Carroll, Hillsborough, Merrimack, Rockingham, Strafford
OK - Le Flore, Sequoyah
SC - Allendale, Anderson, Berkeley, Charleston, Cherokee, Colleton, Dorchester, Greenville, Pickens, Richland, Spartanburg, York
TX - Statewide
VA - Botetourt, Chesapeake City, Franklin, Norfolk City, Portsmouth City, Roanoke, Roanoke City, Salem City, Virginia Beach City, Albemarle, Alexandria City, Arlington, Charlottesville City, Chesterfield, Colonial Heights City, Craig, Dinwiddie, Falls Church City, Fauquier, Floyd, Goochland, Hampton City, Hanover, Henrico, Hopewell City, Isle of Wight, James City, Loudoun, Louisa, Manassas City, Manassas Park City, Montgomery, Newport News City, Petersburg City, Poquoson City, Powhatan, Prince William, Pulaski, Radford City, Richmond City, Suffolk City, Williamsburg City, Wythe, York, Accomack, Alleghany, Amelia, Amherst, Appomattox, Augusta, Bath, Bedford, Bedford City, Bland, Brunswick, Buckingham, Buena Vista City, Campbell, Caroline, Carroll, Charles City, Charlotte, Clarke, Covington City, Culpeper, Cumberland, Danville City, Emporia City, Essex, Fairfax, Fairfax City, Frederick, Fredericksburg City, Galax City, Giles, Gloucester, Greene, Greenville, Halifax, Harrisonburg City, Henry, King and Queen, King George, King William, Lancaster, Lexington City, Lunenburg, Lynchburg City, Madison, Martinsville City, Mathews, Mecklenburg, Middlesex, Nelson, New Kent, Northampton, Northumberland, Nottoway, Orange, Page, Patrick, Pittsylvania, Prince Edward, Prince George, Rappahannock, Richmond, Rockbridge, Rockingham, Shenandoah, Southampton, Spotsylvania, Stafford, Staunton City, Surry, Sussex, Warren, Waynesboro City, Westmoreland, Winchester City, Highland, Franklin City, Fluvanna
WA - Statewide

1 Name of Service Area
WV - Boone, Cabell, Kanawha, Lincoln, McDowell, Mercer, Monroe, Putnam, Barbour, Berkeley, Braxton, Brooke, Calhoun, Clay, Doddridge, Fayette, Gilmer, Grant, Greenbrier, Hampshire, Hancock, Hardy, Harrison, Jackson, Jefferson, Lewis, Logan, Marion, Marshall, Mason, Mineral, Mingo, Monongalia, Morgan, Nicholas, Ohio, Pendleton, Pleasants, Pocahontas, Preston, Raleigh, Randolph, Ritchie, Roane, Summers, Taylor, Tucker, Tyler, Upshur, Wayne, Webster, Wetzel, Wirt, Wood, Wyoming

13.1 Do you act as a custodian for health savings accounts? ..... Yes [ ] No [X]

13.2 If yes, please provide the amount of custodial funds held as of the reporting date. ..... $ 0

13.3 Do you act as an administrator for health savings accounts? ..... Yes [ ] No [X]

13.4 If yes, please provide the balance of funds administered as of the reporting date. ..... $ 0

14.1 Are any of the captive affiliates reported on Schedule S, Part 3, authorized reinsurers? ..... Yes [ ] No [X] N/A [ ]

14.2 If the answer to 14.1 is yes, please provide the following:

1 Company Name	2 NAIC Company Code	3 Domiciliary Jurisdiction	4 Reserve Credit	Assets Supporting Reserve Credit		
				5 Letters of Credit	6 Trust Agreements	7 Other

15. Provide the following for individual ordinary life insurance* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded):

15.1 Direct Premium Written ..... $ 0

15.2 Total Incurred Claims ..... $ 0

15.3 Number of Covered Lives 0

*Ordinary Life Insurance Includes
Term(whether full underwriting, limited underwriting, jet issue, "short form app")
Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")
Variable Life (with or without secondary gurarantee)
Universal Life (with or without secondary gurarantee)
Variable Universal Life (with or without secondary gurarantee)

16. Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? ..... Yes [X] No [ ]

16.1 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity? ..... Yes [ ] No [ ]

FIVE-YEAR HISTORICAL DATA

		1 2020	2 2019	3 2018	4 2017	5 2016
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	1,596,487,759	1,246,852,729	834,259,468	305,860,486	275,771,796
2.	Total liabilities (Page 3, Line 24)	717,442,530	530,084,291	322,774,745	68,333,037	104,763,026
3.	Statutory minimum capital and surplus requirement	689,225,204	543,228,441	427,209,750	100,446,839	101,611,763
4.	Total capital and surplus (Page 3, Line 33)	879,045,229	716,768,438	511,484,723	237,527,449	171,008,770
	Income Statement (Page 4)					
5.	Total revenues (Line 8)	5,513,801,635	4,345,827,532	3,417,678,000	803,574,710	812,894,102
6.	Total medical and hospital expenses (Line 18)	4,577,042,968	3,671,074,034	2,873,947,669	702,239,558	776,965,082
7.	Claims adjustment expenses (Line 20)	169,390,602	142,602,865	101,885,116	18,623,858	23,481,445
8.	Total administrative expenses (Line 21)	599,873,472	393,467,927	365,138,130	78,617,150	86,013,654
9.	Net underwriting gain (loss) (Line 24)	167,494,594	138,682,706	76,707,085	24,957,144	(60,891,079)
10.	Net investment gain (loss) (Line 27)	32,470,832	33,187,819	17,518,789	4,577,631	2,038,936
11.	Total other income (Lines 28 plus 29)	49	90	94	(2)	(165)
12.	Net income or (loss) (Line 32)	140,113,520	134,476,909	59,729,263	28,999,326	(41,152,859)
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	242,554,123	283,368,857	207,595,571	(2,790,557)	(770,877)
	Risk-Based Capital Analysis					
14.	Total adjusted capital	879,045,229	716,768,438	511,484,723	237,527,449	171,008,770
15.	Authorized control level risk-based capital	137,325,207	108,214,412	85,795,196	18,003,847	20,507,625
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7)	445,510	385,108	323,381	79,533	82,418
17.	Total members months (Column 6, Line 7)	5,179,311	4,461,256	3,792,467	932,334	969,343
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)	83.0	84.5	84.1	87.4	95.6
20.	Cost containment expenses	2.6	2.8	2.5	2.0	2.5
21.	Other claims adjustment expenses	0.5	0.5	0.5	0.3	0.4
22.	Total underwriting deductions (Line 23)	97.0	96.8	97.8	96.9	107.5
23.	Total underwriting gain (loss) (Line 24)	3.0	3.2	2.2	3.1	(7.5)
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 13, Col. 5)	363,574,992	222,912,075	41,616,444	57,916,286	6,629,883
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	361,247,174	235,169,737	37,628,163	68,265,438	6,971,233
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	0
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)	0	0	0	0	0
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0	0	0	0
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	0
30.	Affiliated mortgage loans on real estate	0	0	0	0	0
31.	All other affiliated	0	0	0	0	0
32.	Total of above Lines 26 to 31	0	0	0	0	0
33.	Total investment in parent included in Lines 26 to 31 above.	0	0	0	0	0

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3, Accounting Changes and Correction of Errors? Yes [ ] No [ ]

If no, please explain:

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

States, etc.		1 Active Status (a)	Direct Business Only 2 Accident & Health Premiums	3 Medicare Title XVIII	4 Medicaid Title XIX	5 Federal Employees Health Benefits Plan Premiums	6 Life & Annuity Premiums & Other Considerations	7 Property/ Casualty Premiums	8 Total Columns 2 Through 7	9 Deposit-Type Contracts
1. Alabama	AL	L	0	542,974,104	0	0	0	0	542,974,104	0
2. Alaska	AK	N	0	0	0	0	0	0	0	0
3. Arizona	AZ	L	0	0	0	0	0	0	0	0
4. Arkansas	AR	L	0	464,206,905	0	0	0	0	464,206,905	0
5. California	CA	L	0	1,186,099,608	0	0	0	0	1,186,099,608	0
6. Colorado	CO	N	0	0	0	0	0	0	0	0
7. Connecticut	CT	N	0	0	0	0	0	0	0	0
8. Delaware	DE	N	0	0	0	0	0	0	0	0
9. District of Columbia	DC	N	0	0	0	0	0	0	0	0
10. Florida	FL	N	0	0	0	0	0	0	0	0
11. Georgia	GA	N	0	0	0	0	0	0	0	0
12. Hawaii	HI	N	0	0	0	0	0	0	0	0
13. Idaho	ID	L	0	25,556,540	0	0	0	0	25,556,540	0
14. Illinois	IL	N	0	0	0	0	0	0	0	0
15. Indiana	IN	L	0	879,711,859	0	0	0	0	879,711,859	0
16. Iowa	IA	N	0	0	0	0	0	0	0	0
17. Kansas	KS	N	0	0	0	0	0	0	0	0
18. Kentucky	KY	L	0	335,743,768	0	0	0	0	335,743,768	0
19. Louisiana	LA	N	0	0	0	0	0	0	0	0
20. Maine	ME	L	0	85,766,153	0	0	0	0	85,766,153	0
21. Maryland	MD	N	0	0	0	0	0	0	0	0
22. Massachusetts	MA	N	0	0	0	0	0	0	0	0
23. Michigan	MI	N	0	0	0	0	0	0	0	0
24. Minnesota	MN	N	0	0	0	0	0	0	0	0
25. Mississippi	MS	N	0	0	0	0	0	0	0	0
26. Missouri	MO	L	0	0	0	0	0	0	0	0
27. Montana	MT	N	0	0	0	0	0	0	0	0
28. Nebraska	NE	L	0	(78,380)	0	0	0	0	(78,380)	0
29. Nevada	NV	N	0	0	0	0	0	0	0	0
30. New Hampshire	NH	L	0	35,880,415	0	0	0	0	35,880,415	0
31. New Jersey	NJ	N	0	0	0	0	0	0	0	0
32. New Mexico	NM	N	0	0	0	0	0	0	0	0
33. New York	NY	N	0	0	0	0	0	0	0	0
34. North Carolina	NC	N	0	0	0	0	0	0	0	0
35. North Dakota	ND	N	0	0	0	0	0	0	0	0
36. Ohio	OH	N	0	0	0	0	0	0	0	0
37. Oklahoma	OK	L	0	0	0	0	0	0	0	0
38. Oregon	OR	N	0	0	0	0	0	0	0	0
39. Pennsylvania	PA	N	0	0	0	0	0	0	0	0
40. Rhode Island	RI	N	0	0	0	0	0	0	0	0
41. South Carolina	SC	L	0	919,550,676	0	0	0	0	919,550,676	0
42. South Dakota	SD	N	0	0	0	0	0	0	0	0
43. Tennessee	TN	N	0	0	0	0	0	0	0	0
44. Texas	TX	L	0	0	0	0	0	0	0	0
45. Utah	UT	N	0	0	0	0	0	0	0	0
46. Vermont	VT	N	0	0	0	0	0	0	0	0
47. Virginia	VA	L	0	423,800,286	0	0	0	0	423,800,286	0
48. Washington	WA	L	0	574,987,590	0	0	0	0	574,987,590	0
49. West Virginia	WV	L	0	39,602,111	0	0	0	0	39,602,111	0
50. Wisconsin	WI	N	0	0	0	0	0	0	0	0
51. Wyoming	WY	N	0	0	0	0	0	0	0	0
52. American Samoa	AS	N	0	0	0	0	0	0	0	0
53. Guam	GU	N	0	0	0	0	0	0	0	0
54. Puerto Rico	PR	N	0	0	0	0	0	0	0	0
55. U.S. Virgin Islands	VI	N	0	0	0	0	0	0	0	0
56. Northern Mariana Islands	MP	N	0	0	0	0	0	0	0	0
57. Canada	CAN	N	0	0	0	0	0	0	0	0
58. Aggregate other alien	OT	XXX	0	0	0	0	0	0	0	0
59. Subtotal		XXX	0	5,513,801,635	0	0	0	0	5,513,801,635	0
60. Reporting entity contributions for Employee Benefit Plans		XXX	0	0	0	0	0	0	0	0
61. Total (Direct Business)		XXX	0	5,513,801,635	0	0	0	0	5,513,801,635	0
DETAILS OF WRITE-INS										
58001.		XXX	0	0	0	0	0	0	0	0
58002.		XXX								
58003.		XXX								
58998. Summary of remaining write-ins for Line 58 from overflow page		XXX	0	0	0	0	0	0	0	0
58999. Totals (Lines 58001 through 58003 plus 58998)(Line 58 above)		XXX	0	0	0	0	0	0	0	0

(a) Active Status Counts:

L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG 17
R - Registered - Non-domiciled RRGs 0
E - Eligible - Reporting entities eligible or approved to write surplus lines in the state 0
Q - Qualified - Qualified or accredited reinsurer 0
N - None of the above - Not allowed to write business in the state 40

(b) Explanation of basis of allocation by states, premiums by state, etc.
The Company reports premium based on the situs of the contract



Note: Heavily Outlined Boxes indicates 100% ownership by Humana Inc.
(1) Ownership is 50% by CareNetwork, Inc. and 50% by Centers For Independence, Inc., an unaffiliated entity.
(2) Fully diluted ownership which includes Common and Preferred Units is as follows: HUM-e-FL, Inc. – 16.587%; Navigy, Inc. (an unaffiliated entity)-23.843%; Health Care Service Corporation (an unaffiliated entity)-23.843%; Sellcore, Inc. (an unaffiliated entity)-14.474%; MII Services, Inc. (an unaffiliated entity)-2.239%; and AV Investor, L.L.C. (an unaffiliated entity)-19.013%.
(3) Of the 11,000,000 shares authorized, Humana Innovation Enterprises, Inc. was granted 4,083,333 Common Shares and 650,000 Series A Preferred Shares; additional shares granted as follows: Flare Capital Partners, 1,500,000 Series A Preferred Shares; Define Ventures, 650,000 Series A Preferred Shares; and Stock Options to be awarded to Employees - 3,916,667 shares.
NOTE: See Joint Venture organizational chart for information on the company's ownership in several joint ventures.


Companies with Employees
Licensed Companies
Humana Inc.
(Delaware)
61-0647538
As of 12.31.2020
Humana at Home, Inc.
(f/k/a SeniorBridge Family Companies, Inc.)
13-4036798 (01/21/2000 - DE)
Acq. 07/06/2012
SeniorBridge Family Companies (FL), Inc.
65-1096853
(03/28/2001 - FL)
SeniorBridge Family Companies (IN), Inc.
20-0301155
(09/22/2003 - IN)
SeniorBridge Family Companies (NY), Inc.
36-4484443
(11/29/2001 - NY)
Humana at Home (San Antonio), Inc.
01-0766084
(01/31/2003 -TX)
ROHC, L.L.C.
75-2844854
(10/18/1999 - TX)
Humana At Home (Dallas), Inc.
75-2739333
(12/22/1997 - TX)
Humana At Home (Houston), Inc.
76-0537878
(05/20/1997 - TX)
Humana At Home (TLC), Inc.
75-2600512
(06/12/1995 - TX)
Care Partners Home Care, LLC
26-0815856
(06/26/2009 - FL)
SeniorBridge-Florida, LLC
59-2518701
(08/1/2008 - FL)
Naples Health Care Specialists, LLC
65-0992582
(12/08/2008 - FL)
Nursing Solutions, LLC
65-0688221
(04/30/2009 - FL)
Complex Clinical Management, Inc.
45-3713941
(10/26/2011 - FL)
Management Service Agreement
NO OWNERSHIP INTEREST
Humana Home Advantage (TX), P.A.
FEIN# 81-0789608
Created for Chronic Care Nurse Practitioner Program. Incorporated in Texas on 12/04/2015.
Giridhar Chilukuri 100%
Contractual relationship between Humana Home Advantage (TX), P.A. and Complex Clinical Management, Inc.



Physician Ownership of PAs and PCs

1) Conviva Medical Center Management of Texas, P.A. - Janell Wilson, M.D. - 100%
2) Conviva Physician Group, PLLC - Steve Lee, M.D. – 100%
3) Edge Health, P.C. - Freeman Tich Changamire, M.D. – 100%
4) MCCI of Texas Primary Care Group, PLLC – Janell Wilson, M.D. – 100%
5) Partners in Primary Care (GA), P.C. - Lily-Lan Nhu Pham, M.D. – 100%
6) Partners in Primary Care (NC), P.C. - Erica Savage-Jeter, M.D – 100%.
7) Transcend Community Physician Network, P.C. - John Pigott, M.D – 100%.
8) Transcend Community Physician Network (AR), P.A - Mariolga Mercado, D.O. - 100%
9) Transcend Community Physician Network (KS), P.A. - Elizabeth S. Peterson, M.D. - 100%

OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Exhibit of Nonadmitted Assets Line 25

	1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
2504. Deposits	0	71,616	71,616
2597. Summary of remaining write-ins for Line 25 from overflow page	0	71,616	71,616